

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 March 2002 (14.03.2002)

PCT

(10) International Publication Number
WO 02/20733 A2(51) International Patent Classification⁷: C12N 9/00

(21) International Application Number: PCT/US01/26852

(22) International Filing Date: 29 August 2001 (29.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/229,907 1 September 2000 (01.09.2000) US(71) Applicant (for all designated States except US): E.I. DUPONT DE NEMOURS AND COMPANY [US/US];
Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHENG, Qiong


[CN/US]; 4 Collins Drive, Wilmington, DE 19803 (US).
KOFFAS, Mattheos [GR/US]; 1013 Cloister Road, Apartment D, Wilmington, DE 19809 (US). NORTON, Kelley, C. [US/US]; 8 Sullivan Chase Drive, Avondale, PA 19311 (US). ODOM, James, M. [US/US]; 19 Fern Hill Road, Kennett Square, PA 19348 (US). PICATAGGIO, Stephen, K. [US/US]; 17 Meadow Wood Lane, Landenberg, PA 19350 (US). ROUVIERE, Pierre, E. [FR/US]; 737 Taunton Road, Wilmington, DE 19803 (US). SCHENZLE, Andreas [DE/CH]; Badenerstrasse 363, CH-8003 Zuerich (CH). TOMB, Jean-Francois [US/US]; 627 Haverhill Road, Wilmington, DE 19803 (US).

(74) Agent: FELTHAM, S., Neil; E.I. Dupont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

[Continued on next page]

(54) Title: GENES INVOLVED IN ISOPRENOID COMPOUND PRODUCTION

(57) Abstract: Genes have been isolated from *Methylomonas 16a sp.* encoding the isoprenoid biosynthetic pathway. The genes and gene products are the first isolated from a *Methylomonas* strain that is capable of utilizing single carbon (C1) substrates as energy sources. The genes and gene products of the present invention may be used in a variety of ways for the production of isoprenoid compounds in a variety of organisms.

WO 02/20733 A2



CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TITLE

GENES INVOLVED IN ISOPRENOID COMPOUND PRODUCTION

This application claims the benefit of U.S. Provisional Application No. 60/229,907, filed September 1, 2001.

5

FIELD OF THE INVENTION

This invention is in the field of microbiology. More specifically, this invention pertains to nucleic acid fragments encoding enzymes useful for microbial production of isoprenoid compounds.

BACKGROUND OF THE INVENTION

10

Isoprenoids are an extremely large and diverse group of natural products that have a common biosynthetic origin, i.e., a single metabolic precursor, isopentenyl diphosphate (IPP). The group of natural products known as isoprenoids includes all substances that are derived biosynthetically from the 5-carbon compound isopentenyl diphosphate.

15

Isoprenoid compounds are also referred to as "terpenes" or "terpenoids", which is the term used in the designation of the various classes of these examples (Spurgeon and Porter, *Biosynthesis of Isoprenoid Compounds*, pp 3-46, A Wiley-Interscience Publication (1981)).

20

Isoprenoids are ubiquitous compounds found in all living organisms. Some of the well-known examples of isoprenoids are steroids (triterpenes), carotenoids (tetraterpenes), and squalene, just to name a few.

25

For many years, it was accepted that IPP was synthesized through the well-known acetate/mevalonate pathway. However, recent studies have demonstrated that the mevalonate-dependent pathway does not operate in all living organisms. An alternate mevalonate-independent pathway for IPP biosynthesis was initially characterized in bacteria and later also in green algae and higher plants (Horbach *et al.*, *FEMS Microbiol. Lett.* 111:135-140 (1993); Rohmer *et al.*, *Biochem.* 295: 517-524 (1993); Schwender *et al.*, *Biochem.* 316: 73-80 (1996); Eisenreich *et al.*, *Proc. Natl. Acad. Sci. USA* 93: 6431-6436 (1996)).

30

Many steps in both the mevalonate-independent and mevalonate-dependent isoprenoid pathways are known. For example, the initial steps of the alternate pathway involve the condensation of 3-carbon molecules (pyruvate and C1 aldehyde group, D-glyceraldehyde 3-phosphate), to yield the 5-carbon compound D-1-deoxyxylulose-5-phosphate. Lois *et al.* has reported a gene, *dxs*, that encodes D-1-deoxyxylulose-5-phosphate

35

synthase (DXS) and that catalyzes the synthesis of D-1-deoxyxylulose-5-phosphate in *E. coli* (*Proc. Natl. Acad. Sci. USA* 95: 2105-2110 (1998)).

Next, the isomerization and reduction of D-1-deoxyxylulose-5-phosphate yields 2-C-methyl-D-erythritol-4-phosphate. One of the
5 enzymes involved in the isomerization and reduction process is D-1-deoxyxylulose-5-phosphate reductoisomerase (DXR). Takahashi et al. reported that the *dxr* gene product catalyzes the formation of 2-C-methyl-D-erythritol-4-phosphate in the alternate pathway in *E. coli* (*Proc. Natl. Acad. Sci. USA* 95: 9879-9884 (1998)).

10 Steps converting 2-C-methyl-D-erythritol-4-phosphate to isopentenyl monophosphate are not well characterized, although some steps are known. 2-C-methyl-D-erythritol-4-phosphate is converted into 4-diphosphocytidyl-2C-methyl-D-erythritol in a CTP dependent reaction by the enzyme encoded by non-annotated gene *ygbP*. Rohdich et al.
15 reported that the YgbP protein in *E. coli* catalyzes the reaction mentioned above. Recently, *ygbP* gene was renamed as *ispD* as a part of the *isp* gene cluster (SwissProt#Q46893) (*Proc. Natl. Acad. Sci. USA* 96:11758-11763 (1999)).

Then the 2 position hydroxy group of 4-diphosphocytidyl-2C-methyl-
20 D-erythritol can be phosphorylated in an ATP dependent reaction by the enzyme encoded by the *ychB* gene. Luttgen et al. has reported that the YchB protein in *E. coli* phosphorylates 4-diphosphocytidyl-2C-methyl-D-erythritol, resulting in 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate. Recently, the *ychB* gene was renamed as *ispE* as a part of
25 the *isp* gene cluster (SwissProt#P24209) (Luttgen et al., *Proc. Natl. Acad. Sci. USA* 97:1062-1067 (2000)).

Herz et al. reported that the *ygbB* gene product in *E. coli* converts 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate to 2C-methyl-D-erythritol 2,4-cyclodiphosphate. 2C-methyl-D-erythritol 2,4-
30 cyclodiphosphate can be further converted into carotenoids through the carotenoid biosynthesis pathway (*Proc. Natl. Acad. Sci. USA* 97:2486-2490 (2000)). Recently, the *ygbB* gene was renamed as *ispF* as a part of the *isp* gene cluster (SwissProt #P36663).

The reaction catalyzed by the YgbP enzyme is carried out in a CTP
35 dependent manner. Thus, CTP synthase plays an important role in the isoprenoid pathway. PyrG encoded by the *pyrG* gene in *E. coli* was determined to encode CTP synthase (Weng et al., *J. Biol. Chem.*, 261:5568-5574 (1986)).

Following several reactions not yet characterized, isopentenyl monophosphate is formed. Isopentenyl monophosphate is converted to isopentenyl diphosphate (IPP) by isopentenyl monophosphate kinase, encoded by the *ipk* gene, and that is identical to the above mentioned
5 *yhcB* (*ispE*) gene (Lange and Croteau, *Proc. Natl. Acad. Sci. USA* 96:13714-13719 (1999)).

Cunningham et al. (*J of Bacteriol.* 182:5841-5848, (2000)) has reported that the *lytB* gene in *E. coli* that is thought to encode an enzyme of the deoxyxylulose-5-phosphate pathway that catalyzes a step at or
10 subsequent to the point at which the pathway branches to form IPP and dimethylallyl diphosphate. *LytB* gene is also found in other microorganisms such as *Acinetbacter* and *Synechocystis*, (GenBank Accession Numbers AF027189 and U38915, respectively).

Prenyltransferases constitute a broad group of enzymes catalyzing
15 the consecutive condensation of isopentenyl diphosphate (IPP) resulting in the formation of prenyl diphosphates of various chain lengths. Homologous genes of prenyl transferase have highly conserved regions in their amino acid sequences. Ohto et al. reported three prenyl transferase genes in cyanobacterium *Synechococcus elongatus* (*Plant Mol. Biol.*
20 40:307-321 (1999)). They are geranylgeranyl (C20) diphosphate synthase, farnesyl (C15) diphosphate synthase and another prenyltransferase that can catalyze the synthesis of five prenyl diphosphates of various lengths.

Further down in the isoprenoid biosynthesis pathway, more genes
25 are involved in the synthesis of specific isoprenoids. As an example, the *crtN* gene was found in *Heliobacillus mobilis* (Xiang et al., *Proc. Natl. Acad. Sci. USA* 95:14851-14856 (1998)) to encode diapophytoene dehydrogenase is a part of the carotenoid biosynthesis pathway.

Although most of the genes involved in the isoprenoid pathways are
30 known, the genes involved in the isoprenoid pathway of methanotrophic bacteria are not described in the existing literature. However, there are many pigmented methylotrophic and methanotrophic bacteria, which suggests that the ability to produce carotenoid pigments is widespread in these bacteria and therefore the genes must be widespread in these
35 bacteria. Applicants have isolated a number of unique open reading frames encoding enzymes of the isoprenoid biosynthesis pathway from a *Methylomonas* sp.

Applicants have solved the stated problem by isolating genes containing 9 open reading frames (ORFs) encoding enzymes involved in isoprenoid synthesis.

SUMMARY OF THE INVENTION

5 The present invention provides an isolated nucleic acid molecule encoding a isoprenoid biosynthetic enzyme, selected from the group consisting of: (a) an isolated nucleic acid molecule encoding the amino acid sequence selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18 and 24; (b) an isolated nucleic acid molecule that
10 hybridizes with (a) under the following hybridization conditions: 0.1X SSC, 0.1% SDS, 65°C and washed with 2X SSC, 0.1% SDS followed by 0.1X SSC, 0.1% SDS; and (c) an isolated nucleic acid molecule that is complementary to (a) or (b).

 Additionally the invention provides polypeptides encoded by the
15 present genes and chimera where the genes are under the control of suitable regulatory sequences. Similarly the invention provides transformed organisms, including bacteria, yeast, filamentous fungi, and green plants expressing one or more of the present genes and gene products.

20 The present invention provides methods of obtaining all or substantial portions of the instant genes through gene amplification or hybridization methods.

 In another embodiment the invention provides methods for the production of isoprenoids comprising: contacting a transformed host cell
25 under suitable growth conditions with an effective amount of a carbon source whereby an isoprenoid compound is produced, said transformed host cell comprising a set of nucleic acid molecules encoding SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, and 24 under the control of suitable regulatory sequences.

30 Similarly the invention provides a method of regulating isoprenoid biosynthesis in an organism comprising, over-expressing at least one isoprenoid gene selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17 and 23 in an organism such that the isoprenoid biosynthesis is altered in the organism.

35 In another embodiment the invention provides a mutated gene encoding a isoprenoid enzyme having an altered biological activity produced by a method comprising the steps of (i) digesting a mixture of

nucleotide sequences with restriction endonucleases wherein said mixture comprises:

- a) a native isoprenoid gene;
- b) a first population of nucleotide fragments which will hybridize to said native isoprenoid gene;
- c) a second population of nucleotide fragments which will not hybridize to said native isoprenoid gene;

wherein a mixture of restriction fragments are produced; (ii) denaturing said mixture of restriction fragments; (iii) incubating the denatured said mixture of restriction fragments of step (ii) with a polymerase; (iv) repeating steps (ii) and (iii) wherein a mutated isoprenoid gene is produced encoding a protein having an altered biological activity.

BRIEF DESCRIPTION OF THE DRAWINGS.

SEQUENCE DESCRIPTIONS, AND THE BIOLOGICAL DEPOSITS

Figure 1 shows the isoprenoid pathway.

Figure 2 shows two gene clusters contain genes in the isoprenoid pathway. One cluster contains the *ispD*, *ispF* and *pyrG* genes, and the other cluster contains the *crtN1* and *crtN2* genes.

Figure 3a shows a gene dose effect on carotenoid biosynthesis. Two cultures of the native strain of *Methylobacter 16a*, designated as 16a, and two cultures of a rif-resistant variant of the native strain, designated as 16a-rif (without plasmid), served as negative controls. Six isolated transconjugants were labeled as DXP-1 through DPX-6. Figure 3b shows the plasmid that contains the *dxs* and *dxr* genes.

The invention can be more fully understood from the following detailed description and the accompanying sequence descriptions, which form a part of this application.

The following sequences comply with 37 C.F.R. 1.821-1.825 ("Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures - the Sequence Rules") and are consistent with World Intellectual Property Organization (WIPO) Standard ST.25 (1998) and the sequence listing requirements of the EPO and PCT (Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of the Administrative Instructions). The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

SEQ ID NO:1 is the nucleotide sequence of ORF 1 encoding the *dxs* gene.

SEQ ID NO:2 is the deduced amino acid sequence of *dxs* encoded by ORF 1.

SEQ ID NO:3 is the nucleotide sequence of ORF 2 encoding the *dxr* gene.

5 SEQ ID NO:4 is the deduced amino acid sequence of *dxr* encoded by ORF 2.

SEQ ID NO:5 is the nucleotide sequence of ORF 3 encoding the *ygbP (ispD)* gene.

10 SEQ ID NO:6 is the deduced amino acid sequence of *ygbP (ispD)* gene encoded by ORF 3.

SEQ ID NO:7 is the nucleotide sequence of ORF 4 encoding the *ychB (ispE)* gene.

SEQ ID NO:8 is the deduced amino acid sequence of *ychB (ispE)* encoded by ORF 4.

15 SEQ ID NO:9 is the nucleotide sequence of ORF 5 encoding the *ygbB (ispF)* gene.

SEQ ID NO:10 is the deduced amino acid sequence of *ygbB (ispF)* encoded by ORF 5.

20 SEQ ID NO:11 is the nucleotide sequence of ORF 6 encoding the *pyrG* gene.

SEQ ID NO:12 is the deduced amino acid sequence of *pyrG* encoded by ORF 6.

SEQ ID NO:13 is the nucleotide sequence of ORF 7 encoding the *ispA* gene.

25 SEQ ID NO:14 is the deduced amino acid sequence of *ispA* gene encoded by ORF 7.

SEQ ID NO:15 is the nucleotide sequence of ORF 8 encoding the *crtN* gene, copy1.

30 SEQ ID NO:16 is the deduced amino acid sequence of *crtN* gene copy1 encoded by ORF 8.

SEQ ID NO:17 is the nucleotide sequence of ORF 9 encoding the *crtN* gene copy2.

SEQ ID NO:18 is the deduced amino acid sequence of *crtN* gene copy2 encoded by ORF 9.

35 SEQ ID NO:19 and 20 are the primer sequences used to amplify the *dxs* gene.

SEQ ID NO:21 and 22 are the primer sequences used to amplify the *dxr* gene.

SEQ ID NO:23 is the nucleotide sequence of ORF 10 encoding the *lytB* gene.

SEQ ID NO:24 is the deduced amino acid sequence of the *lytB* gene encoded by ORF 10.

- 5 Applicants made the following biological deposits under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for the Purposes of Patent Procedure:

Depositor Identification Reference	International Depository Designation	Date of Deposit
<i>Methylomonas</i> 16a	ATCC PTA 2402	August 21 2000

10 DETAILED DESCRIPTION OF THE INVENTION

The genes and their expression products are useful for the creation of recombinant organisms that have the ability to produce various isoprenoid compounds. Nucleic acid fragments encoding the above mentioned enzymes have been isolated from a strain of *Methylomonas*
 15 *16a* and identified by comparison to public databases containing nucleotide and protein sequences using the BLAST and FASTA algorithms well known to those skilled in the art.

The genes and gene products of the present invention may be used in a variety of ways for the enhancement or manipulation of isoprenoid
 20 compounds.

The microbial isoprenoid pathway is naturally a multi-product platform for production of compounds such as carotenoids, quinones, squalene, and vitamins. These natural products may be from 5 carbon units to more than 55 carbon units in chain length. There is a general
 25 practical utility for microbial isoprenoid production for carotenoid compounds as these compounds are very difficult to make chemically (Nelis and Leenheer, *Appl. Bacteriol.* 70:181-191 (1991)). Most carotenoids have strong color and can be viewed as natural pigments or colorants. Furthermore, many carotenoids have potent antioxidant
 30 properties and thus inclusion of these compounds in the diet is thought to be healthful. Well-known examples are β -carotene and astaxanthin.

In the case of *Methylomonas* 16a, the inherent capacity to produce carotenoids is particularly useful. This is because methanotrophic bacteria have been used for the commercial production of single cell protein and
 35 the protein from these bacteria is known to be efficacious as animal feeds

(Green, Taxonomy of Methylophilic Bacteria. In: Methane and Methanol Utilizers (Biotechnology Handbooks 5) J. Colin Murrell and Howard Dalton eds. 1992 Plenum Press NY. Pp 23-84; BioProtein Manufacture 1989. Ellis Horwood series in applied science and industrial technology. NY:

5 Halstead Press.)

The genes and gene sequences described herein enable one to incorporate the production of healthful carotenoids directly into the single cell protein product derived from *Methylomonas 16a*. This aspect makes this strain or any methanotrophic strain into which these genes are
10 incorporated a more desirable production host for animal feed due to the presence of carotenoids which are known to add desirable pigmentation and health benefits to the feed. Salmon and shrimp aquacultures are particularly useful applications for this invention as carotenoid pigmentation is critically important for the value of these organisms. (F.
15 Shahidi, J.A. Brown, Carotenoid pigments in seafood and aquaculture Critical reviews in food Science 38(1): 1-67 (1998)).

In addition to feed additives, the genes are useful for the production of carotenoids and their derivatives, isoprenoid intermediates and their derivatives, and as pure products useful as pigments, flavors and
20 fragrances.

In this disclosure, a number of terms and abbreviations are used. The following definitions are provided.

"Open reading frame" is abbreviated ORF.

"Polymerase chain reaction" is abbreviated PCR.

25 As used herein, an "isolated nucleic acid fragment" is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.

30 The term "isoprenoid" or "terpenoid" refers to any molecule derived from the isoprenoid pathway including 10-carbon terpenoids and their derivatives, such as carotenoids and xanthophylls.

The term "*Methylomonas 16a*" and "*Methylomonas 16a sp.*" are used interchangeably and refer to the *Methylomonas* strain used in the
35 present invention.

The term "Dxs" refers to the 1-deoxyxylulose-5-phosphate synthase enzyme encoded by the *dxs* gene represented in OFR1.

The term "Dxr" refers to the 1-deoxyxylulose-5-phosphate reductoisomerase enzyme encoded by the *dxr* gene represented in ORF 2.

5 The term "YgbP" or "IspD" refers to the 2C-methyl-D-erythritol cytidyltransferase enzyme encoded by the *ygbP* or *ispD* gene represented in ORF 3. The names of the gene, *ygbP* or *ispD*, are used interchangeably in this application. The names of gene product, YgbP or IspD are used interchangeably in this application.

10 The term "YchB" or "IspE" refers to 4-diphosphocytidyl-2-C-methylerythritol kinase enzyme encoded by *ychB* or *ispE* gene represented in ORF 4. The names of the gene, *ychB* or *ispE*, are used interchangeably in this application. The names of gene product, YchB or IspE are used interchangeably in this application.

15 The term "YgbB" or "IspF" refers to the 2C-methyl-d-erythritol 2,4-cyclodiphosphate synthase enzyme encoded by the *ygbB* or *ispF* gene represented in ORF 5. The names of the gene, *ygbB* or *ispF*, are used interchangeably in this application. The names of gene product, YgbB or IspF are used interchangeably in this application.

20 The term "PyrG" refers to the CTP synthase enzyme encoded by the *pyrG* gene represented in ORF 6.

The term "IspA" refers to the geranyltransferase or farnesyl diphosphate synthase enzyme, as one of the prenyl transferase family encoded by the *ispA* gene represented in ORF 7.

25 The term "CrtN1" or "CrtN, copy1" refers to copy 1 of the diapophytoene dehydrogenase enzyme encoded by the *crtN1* gene represented in ORF 8.

The term "CrtN2" or "CrtN copy2" refers to copy 2 of the diapophytoene dehydrogenase enzyme encoded by the *crtN2* gene represented in ORF 9.

30 The term "LytB" refers to the protein encoded by the *lytB* gene represented in ORF 10, functioning in the formation of IPP and dimethylallyl diphosphate in the isoprenoid pathway.

35 The term "Embden-Meyerhof pathway" refers to the series of biochemical reactions for conversion of hexoses such as glucose and fructose to important cellular 3-carbon intermediates such as glyceraldehyde 3 phosphate, dihydroxyacetone phosphate, phosphoenol pyruvate and pyruvate. These reactions typically proceed with net yield of biochemically useful energy in the form of ATP. The key enzymes unique

to the Embden-Meyerof pathway are the phosphofructokinase and fructose 1,6 biphosphate aldolase.

The term "Entner-Doudoroff pathway" refers to a series of biochemical reactions for conversion of hexoses such as glucose or fructose to the important 3 carbon cellular intermediates pyruvate and glyceraldehyde 3 phosphate without any net production of biochemically useful energy. The key enzymes unique to the Entner-Doudoroff pathway are the 6 phosphogluconate dehydratase and a ketodeoxyphosphogluconate aldolase.

The term "high growth methanotrophic bacterial strain" refers to a bacterium capable of growth with methane or methanol as the sole carbon and energy source and which possess a functional Embden-Meyerof carbon flux pathway resulting in a high rate of growth and yield of cell mass per gram of C1 substrate metabolized. The specific "high growth methanotrophic bacterial strain" described herein is referred to as "*Methylobacter* 16a" or "16a", which terms are used interchangeably.

The term "methanotroph" or "methanotrophic bacteria" will refer to a prokaryotic microorganism capable of utilizing methane as its primary carbon and energy source.

As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the protein encoded by the DNA sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration of gene expression by antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotide bases that do not substantially affect the functional properties of the resulting transcript. It is therefore understood that the invention encompasses more than the specific exemplary sequences.

For example, it is well known in the art that alterations in a gene which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded protein are common. For the purposes of the present invention substitutions are defined as exchanges within one of the following five groups:

1. Small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr (Pro, Gly);
2. Polar, negatively charged residues and their amides: Asp, Asn, Glu, Gln;
- 5 3. Polar, positively charged residues: His, Arg, Lys;
4. Large aliphatic, nonpolar residues: Met, Leu, Ile, Val (Cys); and
5. Large aromatic residues: Phe, Tyr, Trp.

Thus, a codon for the amino acid alanine, a hydrophobic amino
10 acid, may be substituted by a codon encoding another less hydrophobic residue (such as glycine) or a more hydrophobic residue (such as valine, leucine, or isoleucine). Similarly, changes which result in substitution of one negatively charged residue for another (such as aspartic acid for glutamic acid) or one positively charged residue for another (such as
15 lysine for arginine) can also be expected to produce a functionally equivalent product.

In many cases, nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein.

20 Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Moreover, the skilled artisan recognizes that substantially similar sequences encompassed by this invention are also defined by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65°C
25 and washed with 2X SSC, 0.1% SDS followed by 0.1X SSC, 0.1% SDS), with the sequences exemplified herein. Preferred substantially similar nucleic acid fragments of the instant invention are those nucleic acid fragments whose DNA sequences are at least 80% identical to the DNA sequence of the nucleic acid fragments reported herein. More preferred
30 nucleic acid fragments are at least 90% identical to the DNA sequence of the nucleic acid fragments reported herein. Most preferred are nucleic acid fragments that are at least 95% identical to the DNA sequence of the nucleic acid fragments reported herein.

A nucleic acid molecule is "hybridizable" to another nucleic acid
35 molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength. Hybridization and washing conditions are well

known and exemplified in Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1989), particularly Chapter 11 and Table 11.1 therein (entirely incorporated herein by reference). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65°C. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher T_m) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating T_m have been derived (see Sambrook et al., *supra*, 9.50-9.51). For hybridizations with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., *supra*, 11.7-11.8). In one embodiment the length for a hybridizable nucleic acid is at least about 10 nucleotides. Preferable a minimum length for a hybridizable nucleic acid is at least about 15 nucleotides; more preferably at least about 20 nucleotides; and most preferably the length is at least 30 nucleotides. Furthermore, the skilled artisan will recognize that the temperature and wash solution salt

concentration may be adjusted as necessary according to factors such as length of the probe.

A "substantial portion" of an amino acid or nucleotide sequence comprising enough of the amino acid sequence of a polypeptide or the
5 nucleotide sequence of a gene to putatively identify that polypeptide or gene, either by manual evaluation of the sequence by one skilled in the art, or by computer-automated sequence comparison and identification using algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., (1993) *J. Mol. Biol.* 215:403-410; see also
10 www.ncbi.nlm.nih.gov/BLAST/). In general, a sequence of ten or more contiguous amino acids or thirty or more nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene specific oligonucleotide probes comprising
15 20-30 contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12-15 bases may be used as amplification primers in PCR in order to obtain a particular nucleic acid
20 fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises enough of the sequence to specifically identify and/or isolate a nucleic acid fragment comprising the sequence. The instant specification teaches partial or complete amino acid and nucleotide sequences encoding one or more particular microbial proteins.
25 The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those
30 sequences as defined above.

The term "complementary" is used to describe the relationship between nucleotide bases that are capable to hybridizing to one another. For example, with respect to DNA, adenosine is complementary to thymine and cytosine is complementary to guanine. Accordingly, the
35 instant invention also includes isolated nucleic acid fragments that are complementary to the complete sequences as reported in the accompanying Sequence Listing as well as those substantially similar nucleic acid sequences.

The term "percent identity", as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness

5 between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in: Computational Molecular Biology (Lesk, A. M., ed.) Oxford University Press, NY (1988); Biocomputing: Informatics

10 and Genome Projects (Smith, D. W., ed.) Academic Press, NY (1993); Computer Analysis of Sequence Data, Part I (Griffin, A. M., and Griffin, H. G., eds.) Humana Press, NJ (1994); Sequence Analysis in Molecular Biology (von Heinje, G., ed.) Academic Press (1987); and Sequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) Stockton Press, NY

15 (1991). Preferred methods to determine identity are designed to give the best match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Sequence alignments and percent identity calculations may be performed using the Megalign program of the LASERGENE bioinformatics computing

20 suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP

25 PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

Suitable nucleic acid fragments (isolated polynucleotides of the present invention) encode polypeptides that are at least about 70% identical, preferably at least about 80% identical to the amino acid sequences reported herein. Preferred nucleic acid fragments encode

30 amino acid sequences that are about 85% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that are at least about 90% identical to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid sequences that are at least about 95%

35 identical to the amino acid sequences reported herein. Suitable nucleic acid fragments not only have the above homologies but typically encode a polypeptide having at least 50 amino acids, preferably at least 100 amino

acids, more preferably at least 150 amino acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids.

“Codon degeneracy” refers to the nature in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment that encodes all or a substantial portion of the amino acid sequence encoding the instant microbial polypeptides as set forth in SEQ ID NOs. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

“Synthetic genes” can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form gene segments which are then enzymatically assembled to construct the entire gene. “Chemically synthesized”, as related to a sequence of DNA, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of DNA may be accomplished using well-established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the genes can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found

in nature. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign" gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native
5 genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

"Coding sequence" refers to a DNA sequence that codes for a specific amino acid sequence. "Suitable regulatory sequences" refer to
10 nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns,
15 polyadenylation recognition sequences, RNA processing site, effector binding site and stem-loop structure.

"Promoter" refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. Promoters may be
20 derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response
25 to different environmental or physiological conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may
30 have identical promoter activity.

The "3' non-coding sequences" refer to DNA sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation
35 signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA

transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from post-transcriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into protein by the cell. "cDNA" refers to a double-stranded DNA that is complementary to and derived from mRNA. "Sense" RNA refers to RNA transcript that includes the mRNA and so can be translated into protein by the cell. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (U.S. Patent No. 5,107,065; WO 9928508). The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5' non-coding sequence, 3' non-coding sequence, or the coding sequence. "Functional RNA" refers to antisense RNA, ribozyme RNA, or other RNA that is not translated yet has an effect on cellular processes.

The term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide.

"Mature" protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor" protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

The term "signal peptide" refers to an amino terminal polypeptide preceding the secreted mature protein. The signal peptide is cleaved from and is therefore not present in the mature protein. Signal peptides have the function of directing and translocating secreted proteins across cell membranes. Signal peptide is also referred to as signal protein.

"Transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" or "recombinant" or "transformed" organisms.

The terms "plasmid", "vector" and "cassette" refer to an extra chromosomal element often carrying genes which are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA fragments. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. "Transformation cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitate transformation of a particular host cell. "Expression cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.

The term "altered biological activity" will refer to an activity, associated with a protein encoded by a microbial nucleotide sequence which can be measured by an assay method, where that activity is either greater than or less than the activity associated with the native microbial sequence. "Enhanced biological activity" refers to an altered activity that is greater than that associated with the native sequence. "Diminished biological activity" is an altered activity that is less than that associated with the native sequence.

The term "sequence analysis software" refers to any computer algorithm or software program that is useful for the analysis of nucleotide or amino acid sequences. "Sequence analysis software" may be commercially available or independently developed. Typical sequence analysis software will include but is not limited to the GCG suite of programs (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, WI), BLASTP, BLASTN, BLASTX (Altschul et al., *J. Mol. Biol.* 215:403-410 (1990), and DNASTAR (DNASTAR, Inc. 1228 S. Park St. Madison, WI 53715 USA), and the FASTA program incorporating the

Smith-Waterman algorithm (W. R. Pearson, *Comput. Methods Genome Res.*, [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Publisher: Plenum, New York, NY). Within the context of this application it will be understood that where sequence analysis software is used for analysis, that the results of the analysis will be based on the "default values" of the program referenced, unless otherwise specified. As used herein "default values" will mean any set of values or parameters which originally load with the software when first initialized.

Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Sambrook, J., Fritsch, E. F. and Maniatis, T., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989) (hereinafter "Maniatis"); and by Silhavy, T. J., Bennis, M. L. and Enquist, L. W., Experiments with Gene Fusions, Cold Spring Harbor Laboratory Cold Press Spring Harbor, NY (1984); and by Ausubel, F. M. et al., Current Protocols in Molecular Biology, published by Greene Publishing Assoc. and Wiley-Interscience (1987).

Sequence Identification

A variety of nucleotide sequences have been isolated from *Methylobacter 16a* encoding gene products involved in the isoprenoid production pathway. ORF's 1-6 for example encode enzymes early in the isoprenoid pathway (Figure 1) leading to IPP, which is the precursor of all isoprenoid compounds. ORF 7 encodes the IspA enzyme that is involved in elongation by condensing IPP precursors. ORF 8 and ORF 9 are involved more specifically in carotenoid production.

Comparison of the *dxs* nucleotide base and deduced amino acid sequences (ORF 1) to public databases reveals that the most similar known sequences range from a distant as about 60% identical to the amino acid sequence of reported herein over length of 620 amino acids using a Smith-Waterman alignment algorithm (W. R. Pearson, *Comput. Methods Genome Res.*, [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Publisher: Plenum, New York, NY). More preferred amino acid fragments are at least about 80%-90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the amino acid fragments reported herein. Similarly, preferred *Dxs* encoding nucleic acid sequences corresponding to the instant ORF's are those encoding active proteins and which are at least 80% identical to the nucleic acid sequences of reported herein. More

preferred Dxs nucleic acid fragments are at least 90% identical to the sequences herein. Most preferred are Dxs nucleic acid fragments that are at least 95% identical to the nucleic acid fragments reported herein.

Comparison of the Dxr base and deduced amino acid sequence to public databases reveals that the most similar known sequence is 55% identical at the amino acid level over a length of 394 amino acids (ORF 2) using a Smith-Waterman alignment algorithm (W.R. Pearson *supra*). More preferred amino acid fragments are at least about 80%-90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the amino acid fragments reported herein. Similarly, preferred Dxr encoding nucleic acid sequences corresponding to the instant ORF are those encoding active proteins and which are at least 80% identical to the nucleic acid sequences of reported herein. More preferred Dxr nucleic acid fragments are at least 90% identical to the sequences herein. Most preferred are Dxr nucleic acid fragments that are at least 95% identical to the nucleic acid fragments reported herein.

Comparison of the YgbP (IspD) base and deduced amino acid sequences to public databases reveals that the most similar known sequences range from a distant as about 52% identical at the amino acid level over a length of 231 amino acids (ORF 3) using a Smith-Waterman alignment algorithm (W. R. Pearson *supra*). More preferred amino acid fragments are at least about 80%-90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the amino acid fragments reported herein. Similarly, preferred YgbP (IspD) encoding nucleic acid sequences corresponding to the instant ORF are those encoding active proteins and which are at least 80% identical to the nucleic acid sequences of reported herein. More preferred YgbP (IspD) nucleic acid fragments are at least 90% identical to the sequences herein. Most preferred are YgbP (IspD) nucleic acid fragments that are at least 95% identical to the nucleic acid fragments reported herein.

Comparison of the YchB (IspE) base and deduced amino acid sequences to public databases reveals that the most similar known sequences range from a distant as about 50% identical at the amino acid level over a length of 285 amino acids (ORF 4) using a Smith-Waterman alignment algorithm (W. R. Pearson *supra*). More preferred amino acid fragments are at least about 80%-90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the amino acid fragments reported herein. Similarly, preferred YchB

(IspE) encoding nucleic acid sequences corresponding to the instant ORF are those encoding active proteins and which are at least 80% identical to the nucleic acid sequences of reported herein. More preferred YchB (IspE) nucleic acid fragments are at least 90% identical to the sequences
5 herein. Most preferred are YchB (IspE) nucleic acid fragments that are at least 95% identical to the nucleic acid fragments reported herein.

Comparison of the YgbB (IspF) base and deduced amino acid sequences to public databases reveals that the most similar known sequences range from a distant as about 69% identical at the amino acid
10 level over a length of 157 amino acids (ORF 5) using a Smith-Waterman alignment algorithm (W. R. Pearson *supra*). More preferred amino acid fragments are at least about 80%-90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the amino acid fragments reported herein. Similarly, preferred YgbB
15 (IspF) encoding nucleic acid sequences corresponding to the instant ORF are those encoding active proteins and which are at least 80% identical to the nucleic acid sequences of reported herein. More preferred YgbB (IspF) nucleic acid fragments are at least 90% identical to the sequences herein. Most preferred are YgbB (IspF) nucleic acid fragments that are at
20 least 95% identical to the nucleic acid fragments reported herein.

Comparison of the PyrG base and deduced amino acid sequences to public databases reveals that the most similar known sequences range from a distant as about 67% identical at the amino acid level over a length of 544 amino acids (ORF 6) using a Smith-Waterman alignment algorithm
25 (W. R. Pearson *supra*). More preferred amino acid fragments are at least about 80%-90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the amino acid fragments reported herein. Similarly, preferred PyrG encoding nucleic acid sequences corresponding to the instant ORF are those encoding
30 active proteins and which are at least 80% identical to the nucleic acid sequences of reported herein. More preferred PyrG nucleic acid fragments are at least 90% identical to the sequences herein. Most preferred are PyrG nucleic acid fragments that are at least 95% identical to the nucleic acid fragments reported herein.

35 Comparison of the IspA base and deduced amino acid sequences to public databases reveals that the most similar known sequences range from a distant as about 57% identical at the amino acid level over a length of 297 amino acids (ORF 7) using a Smith-Waterman alignment algorithm

(W. R. Pearson *supra*). More preferred amino acid fragments are at least about 80%-90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the amino acid fragments reported herein. Similarly, preferred IspA encoding nucleic acid sequences corresponding to the instant ORF are those encoding active proteins and which are at least 80% identical to the nucleic acid sequences of reported herein. More preferred IspA nucleic acid fragments are at least 90% identical to the sequences herein. Most preferred are IspA nucleic acid fragments that are at least 95% identical to the nucleic acid fragments reported herein.

Comparison of the copy 1 of CrtN base and deduced amino acid sequences to public databases reveals that the most similar known sequences range from a distant as about 34% identical at the amino acid level over a length of 511 amino acids (ORF 8) using a Smith-Waterman alignment algorithm (W. R. Pearson *supra*). More preferred amino acid fragments are at least about 80%-90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the amino acid fragments reported herein. Similarly, preferred nucleic acid sequences corresponding to the instant ORF are those encoding active proteins and which are at least 80% identical to the nucleic acid sequences of reported herein. More preferred nucleic acid fragments are at least 90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the nucleic acid fragments reported herein.

Comparison of the copy 2 of CrtN base and deduced amino acid sequences to public databases reveals that the most similar known sequences range from a distant as about 34% identical at the amino acid level over a length of 497 amino acids (ORF 9) using a Smith-Waterman alignment algorithm (W. R. Pearson *supra*). More preferred amino acid fragments are at least about 80%-90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the amino acid fragments reported herein. Similarly, preferred nucleic acid sequences corresponding to the instant ORF are those encoding active proteins and which are at least 80% identical to the nucleic acid sequences of reported herein. More preferred nucleic acid fragments are at least 90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the nucleic acid fragments reported herein.

Comparison of the LytB base and deduced amino acid sequences to public databases reveals that the most similar known sequences range from a distant as about 65% identical at the amino acid level over a length of 318 amino acids (ORF 10) using a Smith-Waterman alignment algorithm (W. R. Pearson *supra*). It has been reported that expression of *lytB* gene in *E. coli* significantly enhanced accumulation of carotenoids when the *E. coli* was engineered to express carotenoid (Cunningham *et al.*, *J of Bacteriol.* 182:5841-5848 (2000)). More preferred amino acid fragments are at least about 80%-90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the amino acid fragments reported herein. Similarly, preferred nucleic acid sequences corresponding to the instant ORF are those encoding active proteins and which are at least 80% identical to the nucleic acid sequences of reported herein. More preferred nucleic acid fragments are at least 90% identical to the sequences herein. Most preferred are nucleic acid fragments that are at least 95% identical to the nucleic acid fragments reported herein.

Isolation of Homologs

The nucleic acid fragments of the instant invention may be used to isolate genes encoding homologous proteins from the same or other microbial species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g. polymerase chain reaction (PCR), Mullis *et al.*, U.S. Patent 4,683,202), ligase chain reaction (LCR), Tabor, S. *et al.*, *Proc. Acad. Sci. USA* 82, 1074, (1985)) or strand displacement amplification (SDA, Walker, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 89, 392, (1992)).

For example, genes encoding similar proteins or polypeptides to those of the instant invention could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired bacteria using methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, the entire sequences can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primers DNA labeling, nick translation, or

end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part of or full-length of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length DNA fragments under conditions of appropriate stringency.

Typically, in PCR-type amplification techniques, the primers have different sequences and are not complementary to each other. Depending on the desired test conditions, the sequences of the primers should be designed to provide for both efficient and faithful replication of the target nucleic acid. Methods of PCR primer design are common and well known in the art. (Thein and Wallace, "The use of oligonucleotide as specific hybridization probes in the Diagnosis of Genetic Disorders", in *Human Genetic Diseases: A Practical Approach*, K. E. Davis Ed., (1986) pp. 33-50 IRL Press, Herndon, Virginia); Rychlik, W. (1993) In White, B. A. (ed.), Methods in Molecular Biology, Vol. 15, pages 31-39, PCR Protocols: Current Methods and Applications. Humana Press, Inc., Totowa, NJ).

Generally two short segments of the instant sequences may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding microbial genes.

Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al., *PNAS USA* 85:8998 (1988)) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al., *PNAS USA* 86:5673 (1989); Loh et al., *Science* 243:217 (1989)).

Alternatively the instant sequences may be employed as hybridization reagents for the identification of homologs. The basic components of a nucleic acid hybridization test include a probe, a sample

suspected of containing the gene or gene fragment of interest, and a specific hybridization method. Probes of the present invention are typically single stranded nucleic acid sequences which are complementary to the nucleic acid sequences to be detected. Probes are "hybridizable" to the nucleic acid sequence to be detected. The probe length can vary from 5 bases to tens of thousands of bases, and will depend upon the specific test to be done. Typically a probe length of about 15 bases to about 30 bases is suitable. Only part of the probe molecule need be complementary to the nucleic acid sequence to be detected. In addition, the complementarity between the probe and the target sequence need not be perfect. Hybridization does occur between imperfectly complementary molecules with the result that a certain fraction of the bases in the hybridized region are not paired with the proper complementary base.

Hybridization methods are well defined. Typically the probe and sample must be mixed under conditions which will permit nucleic acid hybridization. This involves contacting the probe and sample in the presence of an inorganic or organic salt under the proper concentration and temperature conditions. The probe and sample nucleic acids must be in contact for a long enough time that any possible hybridization between the probe and sample nucleic acid may occur. The concentration of probe or target in the mixture will determine the time necessary for hybridization to occur. The higher the probe or target concentration the shorter the hybridization incubation time needed. Optionally a chaotropic agent may be added. The chaotropic agent stabilizes nucleic acids by inhibiting nuclease activity. Furthermore, the chaotropic agent allows sensitive and stringent hybridization of short oligonucleotide probes at room temperature [Van Ness and Chen (1991) *Nucl. Acids Res.* 19:5143-5151]. Suitable chaotropic agents include guanidinium chloride, guanidinium thiocyanate, sodium thiocyanate, lithium tetrachloroacetate, sodium perchlorate, rubidium tetrachloroacetate, potassium iodide, and cesium trifluoroacetate, among others. Typically, the chaotropic agent will be present at a final concentration of about 3M. If desired, one can add formamide to the hybridization mixture, typically 30-50% (v/v).

Various hybridization solutions can be employed. Typically, these comprise from about 20 to 60% volume, preferably 30%, of a polar organic solvent. A common hybridization solution employs about 30-50% v/v formamide, about 0.15 to 1M sodium chloride, about 0.05 to 0.1M buffers, such as sodium citrate, Tris-HCl, PIPES or HEPES (pH range about 6-9),

about 0.05 to 0.2% detergent, such as sodium dodecylsulfate, or between 0.5-20 mM EDTA, FICOLL (Pharmacia Inc.) (about 300-500 kilodaltons), polyvinylpyrrolidone (about 250-500 kdal), and serum albumin. Also included in the typical hybridization solution will be unlabeled carrier
5 nucleic acids from about 0.1 to 5 mg/mL, fragmented nucleic DNA, e.g., calf thymus or salmon sperm DNA, or yeast RNA, and optionally from about 0.5 to 2% wt./vol. glycine. Other additives may also be included, such as volume exclusion agents which include a variety of polar water-soluble or swellable agents, such as polyethylene glycol, anionic polymers
10 such as polyacrylate or polymethylacrylate, and anionic saccharidic polymers, such as dextran sulfate.

Nucleic acid hybridization is adaptable to a variety of assay formats. One of the most suitable is the sandwich assay format. The sandwich assay is particularly adaptable to hybridization under non-denaturing
15 conditions. A primary component of a sandwich-type assay is a solid support. The solid support has adsorbed to it or covalently coupled to it immobilized nucleic acid probe that is unlabeled and complementary to one portion of the sequence.

Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening DNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These
25 antibodies can be then be used to screen DNA expression libraries to isolate full-length DNA clones of interest (Lerner, R. A. *Adv. Immunol.* 36:1 (1984); Maniatis).

Recombinant Expression - Microbial

The genes and gene products of the instant sequences may be
30 produced in heterologous host cells, particularly in the cells of microbial hosts. Expression in recombinant microbial hosts may be useful for the expression of various pathway intermediates, or for the modulation of pathways already existing in the host for the synthesis of new products heretofore not possible using the host.

35 Preferred heterologous host cells for expression of the instant genes and nucleic acid fragments are microbial hosts that can be found broadly within the fungal or bacterial families and which grow over a wide range of temperature, pH values, and solvent tolerances. For example, it

is contemplated that any bacteria, yeast, and filamentous fungi will be suitable hosts for expression of the present nucleic acid fragments. Because of transcription, translation and the protein biosynthetic apparatus is the same irrespective of the cellular feedstock, functional genes are expressed irrespective of carbon feedstock used to generate cellular biomass. Large-scale microbial growth and functional gene expression may utilize a wide range of simple or complex carbohydrates, organic acids and alcohols, and/or saturated hydrocarbons such as methane or carbon dioxide in the case of photosynthetic or chemoautotrophic hosts. However, the functional genes may be regulated, repressed or depressed by specific growth conditions, which may include the form and amount of nitrogen, phosphorous, sulfur, oxygen, carbon or any trace micronutrient including small inorganic ions. In addition, the regulation of functional genes may be achieved by the presence or absence of specific regulatory molecules that are added to the culture and are not typically considered nutrient or energy sources. Growth rate may also be an important regulatory factor in gene expression. Examples of host strains include but are not limited to fungal or yeast species such as *Aspergillus*, *Trichoderma*, *Saccharomyces*, *Pichia*, *Candida*, *Hansenula*, or bacterial species such as *Salmonella*, *Bacillus*, *Acinetobacter*, *Rhodococcus*, *Streptomyces*, *Escherichia*, *Pseudomonas*, *Methylomonas*, *Methylobacter*, *Methylococcus*, *Methylosinus*, *Methylomicrobium*, *Methylocystis*, *Alcaligenes*, *Synechocystis*, *Anabaena*, *Thiobacillus*, *Methanobacterium* and *Klebsiella*.

Of particular interest in the present invention are high growth obligate methanotrophs having an energetically favorable carbon flux pathway. For example Applicants have discovered a specific strain of methanotroph having several pathway features which make it particularly useful for carbon flux manipulation. This type of strain has served as the host in the present application and is known as *Methylomonas 16a* (ATCC PTA 2402).

The present strain contains several anomalies in the carbon utilization pathway. For example, based on genome sequence data, the strain is shown to contain genes for two pathways of hexose metabolism. The Entner-Doudoroff Pathway which utilizes the keto-deoxy phosphogluconate aldolase enzyme is present in the strain. It is generally well accepted that this is the operative pathway in obligate methanotrophs. Also present, however, is the Embden-Meyerhof Pathway, which utilizes

the fructose bisphosphate aldolase enzyme. It is well known that this pathway is either not present or not operative in obligate methanotrophs. Energetically, the latter pathway is most favorable and allows greater yield of biologically useful energy, ultimately resulting in greater yield production of cell mass and other cell mass-dependent products in *Methylomonas* 16a. The activity of this pathway in the present 16a strain has been confirmed through microarray data and biochemical evidence measuring the reduction of ATP. Although the 16a strain has been shown to possess both the Embden-Meyerhof and the Entner-Doudoroff pathway enzymes, the data suggests that the Embden-Meyerhof pathway enzymes are more strongly expressed than the Entner-Doudoroff pathway enzymes. This result is surprising and counter to existing beliefs concerning the glycolytic metabolism of methanotrophic bacteria. Applicants have discovered other methanotrophic bacteria having this characteristic, including for example, *Methylomonas clara* and *Methylosinus sporium*. It is likely that this activity has remained undiscovered in methanotrophs due to the lack of activity of the enzyme with ATP, the typical phosphoryl donor for the enzyme in most bacterial systems.

A particularly novel and useful feature of the Embden-Meyerhof pathway in strain 16a is that the key phosphofructokinase step is pyrophosphate dependent instead of ATP dependent. This feature adds to the energy yield of the pathway by using pyrophosphate instead of ATP. Because of its significance in providing an energetic advantage to the strain, this gene in the carbon flux pathway is considered diagnostic for the present strain.

In methanotrophic bacteria methane is converted to biomolecules via a cyclic set of reactions known as the ribulose monophosphate pathway or RuMP cycle. This pathway is comprised of three phases, each phase being a series of enzymatic steps. The first step is "fixation" or incorporation of C-1 (formaldehyde) into a pentose to form a hexose or six-carbon sugar. This occurs via a condensation reaction between a 5-carbon sugar (pentose) and formaldehyde and is catalyzed by hexulose monophosphate synthase. The second phase is termed "cleavage" and results in splitting of that hexose into two 3-carbon molecules. One of those 3-carbon molecules is recycled back through the RuMP pathway and the other 3-carbon fragment is utilized for cell growth. In methanotrophs and methylotrophs the RuMP pathway may occur as one of three variants. However only two of these variants are commonly found:

the FBP/TA (fructose biphosphotase/Transaldolase) or the KDPG/TA (keto deoxy phosphogluconate/transaldolase) pathway (Dijkhuizen L., G.E. Devries. The Physiology and biochemistry of aerobic methanol-utilizing gram negative and gram positive bacteria. In: Methane and Methanol Utilizers 1992, ed Colin Murrell and Howard Dalton Plenum Press NY).

The present strain is unique in the way it handles the "cleavage" steps where genes were found that carry out this conversion via fructose biphosphate as a key intermediate. The genes for fructose biphosphate aldolase and transaldolase were found clustered together on one piece of DNA. Secondly the genes for the other variant involving the keto deoxy phosphogluconate intermediate were also found clustered together. Available literature teaches that these organisms (obligate methylotrophs and methanotrophs) rely solely on the KDPG pathway and that the FBP-dependent fixation pathway is utilized by facultative methylotrophs (Dijkhuizen et al., *supra*). Therefore the latter observation is expected whereas the former is not. The finding of the FBP genes in an obligate methane utilizing bacterium is both surprising and suggestive of utility. The FBP pathway is energetically favorable to the host microorganism due to the fact that more energy (ATP) is utilized than is utilized in the KDPG pathway. Thus organisms that utilize the FBP pathway may have an energetic advantage and growth advantage over those that utilize the KDPG pathway. This advantage may also be useful for energy-requiring production pathways in the strain. By using this pathway a methane-utilizing bacterium may have an advantage over other methane utilizing organisms as production platforms for either single cell protein or for any other product derived from the flow of carbon through the RuMP pathway.

Accordingly the present invention provides a method for the production of an isoprenoid compound in a high growth, energetically favorable *Methylobacter* strain which

- (a) grows on a C1 carbon substrate selected from the group consisting of methane and methanol; and
- (b) comprises a functional Embden-Meyerhof carbon pathway, said pathway comprising a gene encoding a pyrophosphate dependent phosphofructokinase enzyme.

Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct chimeric genes for production of the any of the gene products of

the instant sequences. These chimeric genes could then be introduced into appropriate microorganisms via transformation to provide high level expression of the enzymes

Accordingly it is expected, for example, that introduction of chimeric genes encoding the instant bacterial enzymes under the control of the appropriate promoters, will demonstrate increased isoprenoid production. It is contemplated that it will be useful to express the instant genes both in natural host cells as well as heterologous host. Introduction of the present genes into native host will result in elevated levels of existing isoprenoid production. Additionally, the instant genes may also be introduced into non-native host bacteria where there are advantages to manipulate the isoprenoid compound production that are not present in *Methanotrophs*.

Vectors or cassettes useful for the transformation of suitable host cells are well known in the art. Typically the vector or cassette contains sequences directing transcription and translation of the relevant gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. It is most preferred when both control regions are derived from genes homologous to the transformed host cell, although it is to be understood that such control regions need not be derived from the genes native to the specific species chosen as a production host.

Initiation control regions or promoters, which are useful to drive expression of the instant ORF's in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genes is suitable for the present invention including but not limited to *CYC1*, *HIS3*, *GAL1*, *GAL10*, *ADH1*, *PGK*, *PHO5*, *GAPDH*, *ADC1*, *TRP1*, *URA3*, *LEU2*, *ENO*, *TPI* (useful for expression in *Saccharomyces*); *AOX1* (useful for expression in *Pichia*); and *lac*, *ara*, *tet*, *trp*, *IP_L*, *IP_R*, *T7*, *tac*, and *trc* (useful for expression in *Escherichia coli*) as well as the *amy*, *apr*, *npr* promoters and various phage promoters useful for expression in *Bacillus*.

Termination control regions may also be derived from various genes native to the preferred hosts. Optionally, a termination site may be unnecessary, however, it is most preferred if included.

Pathway Engineering

Knowledge of the sequence of the present genes will be useful in manipulating the isoprenoid biosynthetic pathways in any organism having

such a pathway and particularly in methanotrophs. Methods of manipulating genetic pathways are common and well known in the art. Selected genes in a particular pathway may be upregulated or down regulated by variety of methods. Additionally, competing pathways
5 organism may be eliminated or sublimated by gene disruption and similar techniques.

Once a key genetic pathway has been identified and sequenced specific genes may be upregulated to increase the output of the pathway. For example, additional copies of the targeted genes may be introduced
10 into the host cell on multicopy plasmids such as pBR322. Alternatively the target genes may be modified so as to be under the control of non-native promoters. Where it is desired that a pathway operate at a particular point in a cell cycle or during a fermentation run, regulated or inducible promoters may used to replace the native promoter of the target gene.
15 Similarly, in some cases the native or endogenous promoter may be modified to increase gene expression. For example, endogenous promoters can be altered *in vivo* by mutation, deletion, and/or substitution (see, Kmiec, U.S. Patent 5,565,350; Zarling *et al.*, PCT/US93/03868).

Alternatively it may be necessary to reduce or eliminate the
20 expression of certain genes in the target pathway or in competing pathways that may serve as competing sinks for energy or carbon. Methods of down-regulating genes for this purpose have been explored. Where sequence of the gene to be disrupted is known, one of the most effective methods gene down regulation is targeted gene disruption where
25 foreign DNA is inserted into a structural gene so as to disrupt transcription. This can be effected by the creation of genetic cassettes comprising the DNA to be inserted (often a genetic marker) flanked by sequence having a high degree of homology to a portion of the gene to be disrupted. Introduction of the cassette into the host cell results in insertion of the
30 foreign DNA into the structural gene via the native DNA replication mechanisms of the cell. (See for example Hamilton *et al.* (1989) *J. Bacteriol.* 171:4617-4622, Balbas *et al.* (1993) *Gene* 136:211-213, Gueldener *et al.* (1996) *Nucleic Acids Res.* 24:2519-2524, and Smith *et al.* (1996) *Methods Mol. Cell. Biol.* 5:270-277.)

35 Antisense technology is another method of down regulating genes where the sequence of the target gene is known. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the anti-sense strand of RNA will be transcribed.

This construct is then introduced into the host cell and the antisense strand of RNA is produced. Antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the protein of interest. The person skilled in the art will know that special considerations
5 are associated with the use of antisense technologies in order to reduce expression of particular genes. For example, the proper level of expression of antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan.

Although targeted gene disruption and antisense technology offer
10 effective means of down regulating genes where the sequence is known, other less specific methodologies have been developed that are not sequence based. For example, cells may be exposed to UV radiation and then screened for the desired phenotype. Mutagenesis with chemical agents is also effective for generating mutants and commonly used
15 substances include chemicals that affect nonreplicating DNA such as HNO₂ and NH₂OH, as well as agents that affect replicating DNA such as acridine dyes, notable for causing frameshift mutations. Specific methods for creating mutants using radiation or chemical agents are well documented in the art. See for example Thomas D. Brock in
20 *Biotechnology: A Textbook of Industrial Microbiology*, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA., or Deshpande, Mukund V., *Appl. Biochem. Biotechnol.*, 36, 227, (1992).

Another non-specific method of gene disruption is the use of
transposoable elements or transposons. Transposons are genetic
25 elements that insert randomly in DNA but can be latter retrieved on the basis of sequence to determine where the insertion has occurred. Both *in vivo* and *in vitro* transposition methods are known. Both methods involve the use of a transposable element in combination with a transposase enzyme. When the transposable element or transposon, is contacted with
30 a nucleic acid fragment in the presence of the transposase, the transposable element will randomly insert into the nucleic acid fragment. The technique is useful for random mutagenesis and for gene isolation, since the disrupted gene may be identified on the basis of the sequence of the transposable element. Kits for *in vitro* transposition are commercially
35 available (see for example The Primer Island Transposition Kit, available from Perkin Elmer Applied Biosystems, Branchburg, NJ, based upon the yeast Ty1 element; The Genome Priming System, available from New England Biolabs, Beverly, MA; based upon the bacterial transposon Tn7;

and the EZ::TN Transposon Insertion Systems, available from Epicentre Technologies, Madison, WI, based upon the Tn5 bacterial transposable element.

Within the context of the present invention it may be useful to modulate the expression of the identified isoprenoid pathway by any one of the above described methods. For example, the present invention provides a number of genes encoding key enzymes in the terpenoid pathway leading to the production of pigments and smaller isoprenoid compounds. The isolated genes include the *dxs* and *dsr* genes, the *ispA*, *D*, *E*, *F*, and *G* genes, the *pyrG* gene and the *crtN* genes. In particular it may be useful to up-regulate the initial condensation of 3-carbon compounds (pyruvate and C1 aldehyde group, D-glyceraldehyde 3-phosphate), to yield the 5-carbon compound D-1-deoxyxylulose-5-phosphate mediated by the *dxs* gene. Alternatively, if it is desired to produce a specific non-pigmented isoprenoid, it may be desirable to disrupt various genes at the downstream end of the pathway. For example, the *crtN* gene is known to encode diapophytoene dehydrogenase, which is a part of the carotenoid biosynthesis pathway. It may be desirable to use gene disruption or antisense inhibition of this gene if a smaller, upstream terpenoid is the desired product of the pathway.

Industrial Production

Where commercial production of the instant proteins are desired a variety of culture methodologies may be applied. For example, large-scale production of a specific gene product, overexpressed from a recombinant microbial host may be produced by both batch or continuous culture methodologies.

A classical batch culturing method is a closed system where the composition of the media is set at the beginning of the culture and not subject to artificial alterations during the culturing process. Thus, at the beginning of the culturing process the media is inoculated with the desired organism or organisms and growth or metabolic activity is permitted to occur adding nothing to the system. Typically, however, a "batch" culture is batch with respect to the addition of carbon source and attempts are often made at controlling factors such as pH and oxygen concentration. In batch systems the metabolite and biomass compositions of the system change constantly up to the time the culture is terminated. Within batch cultures cells moderate through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or

halted. If untreated, cells in the stationary phase will eventually die. Cells in log phase are often responsible for the bulk of production of end product or intermediate in some systems. Stationary or post-exponential phase production can be obtained in other systems.

5 A variation on the standard batch system is the Fed-Batch system. Fed-Batch culture processes are also suitable in the present invention and comprise a typical batch system with the exception that the substrate is added in increments as the culture progresses. Fed-Batch systems are useful when catabolite repression is apt to inhibit the metabolism of the
10 cells and where it is desirable to have limited amounts of substrate in the media. Measurement of the actual substrate concentration in Fed-Batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases such as CO₂. Batch and Fed-Batch culturing
15 methods are common and well known in the art and examples may be found in Thomas D. Brock in *Biotechnology: A Textbook of Industrial Microbiology*, Second Edition (1989) Sinauer Associates, Inc., Sunderland, MA., or Deshpande, Mukund V., *Appl. Biochem. Biotechnol.*, 36, 227, (1992), herein incorporated by reference.

20 Commercial production of the instant proteins may also be accomplished with a continuous culture. Continuous cultures are an open system where a defined culture media is added continuously to a bioreactor and an equal amount of conditioned media is removed simultaneously for processing. Continuous cultures generally maintain the
25 cells at a constant high liquid phase density where cells are primarily in log phase growth. Alternatively continuous culture may be practiced with immobilized cells where carbon and nutrients are continuously added, and valuable products, by-products or waste products are continuously removed from the cell mass. Cell immobilization may be performed using
30 a wide range of solid supports composed of natural and/or synthetic materials.

 Continuous or semi-continuous culture allows for the modulation of one factor or any number of factors that affect cell growth or end product concentration. For example, one method will maintain a limiting nutrient
35 such as the carbon source or nitrogen level at a fixed rate and allow all other parameters to moderate. In other systems a number of factors affecting growth can be altered continuously while the cell concentration, measured by media turbidity, is kept constant. Continuous systems strive

to maintain steady state growth conditions and thus the cell loss due to media being drawn off must be balanced against the cell growth rate in the culture. Methods of modulating nutrients and growth factors for continuous culture processes as well as techniques for maximizing the rate of product formation are well known in the art of industrial microbiology and a variety of methods are detailed by Brock, *supra*.

Fermentation media in the present invention must contain suitable carbon substrates. Suitable substrates may include but are not limited to monosaccharides such as glucose and fructose, oligosaccharides such as lactose or sucrose, polysaccharides such as starch or cellulose or mixtures thereof and unpurified mixtures from renewable feedstocks such as cheese whey permeate, cornsteep liquor, sugar beet molasses, and barley malt. Additionally the carbon substrate may also be one-carbon substrates such as carbon dioxide, methane or methanol for which metabolic conversion into key biochemical intermediates has been demonstrated. In addition to one and two carbon substrates, methylotrophic organisms are also known to utilize a number of other carbon containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity. For example, methylotrophic yeast are known to utilize the carbon from methylamine to form trehalose or glycerol (Bellion et al., *Microb. Growth C1 Compd.*, [Int. Symp.], 7th (1993), 415-32. Editor(s): Murrell, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK). Similarly, various species of *Candida* will metabolize alanine or oleic acid (Sulter et al., *Arch. Microbiol.* 153:485-489 (1990)). Hence it is contemplated that the source of carbon utilized in the present invention may encompass a wide variety of carbon containing substrates and will only be limited by the choice of organism.

Recombinant Expression - Plants

Plants and algae are also known to produce isoprenoid compounds. The nucleic acid fragments of the instant invention may be used to create transgenic plants having the ability to express the microbial protein. Preferred plant hosts will be any variety that will support a high production level of the instant proteins. Suitable green plants will included but are not limited to soybean, rapeseed (*Brassica napus*, *B. campestris*), sunflower (*Helianthus annuus*), cotton (*Gossypium hirsutum*), corn, tobacco (*Nicotiana tabacum*), alfalfa (*Medicago sativa*), wheat (*Triticum sp*), barley (*Hordeum vulgare*), oats (*Avena sativa*, L), sorghum (*Sorghum bicolor*), rice (*Oryza sativa*), *Arabidopsis*, cruciferous vegetables (broccoli, cauliflower,

cabbage, parsnips, etc.), melons, carrots, celery, parsley, tomatoes, potatoes, strawberries, peanuts, grapes, grass seed crops, sugar beets, sugar cane, beans, peas, rye, flax, hardwood trees, softwood trees, and forage grasses. Algal species include but not limited to commercially significant hosts such as *Spirulina* and *Dunalliella*. Overexpression of the isoprenoid compounds may be accomplished by first constructing chimeric genes of present invention in which the coding region are operably linked to promoters capable of directing expression of a gene in the desired tissues at the desired stage of development. For reasons of convenience, the chimeric genes may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription termination signals must also be provided. The instant chimeric genes may also comprise one or more introns in order to facilitate gene expression.

Any combination of any promoter and any terminator capable of inducing expression of a coding region may be used in the chimeric genetic sequence. Some suitable examples of promoters and terminators include those from nopaline synthase (*nos*), octopine synthase (*ocs*) and cauliflower mosaic virus (*CaMV*) genes. One type of efficient plant promoter that may be used is a high level plant promoter. Such promoters, in operable linkage with the genetic sequences or the present invention should be capable of promoting expression of the present gene product. High level plant promoters that may be used in this invention include the promoter of the small subunit (*ss*) of the ribulose-1,5-bisphosphate carboxylase from example from soybean (Berry-Lowe et al., *J. Molecular and App. Gen.*, 1:483-498 1982)), and the promoter of the chlorophyll *a/b* binding protein. These two promoters are known to be light-induced in plant cells (see, for example, Genetic Engineering of Plants, an Agricultural Perspective, A. Cashmore, Plenum, NY (1983), pages 29-38; Coruzzi, G. et al., *The Journal of Biological Chemistry*, 258:1399 (1983), and Dunsmuir, P. et al., *Journal of Molecular and Applied Genetics*, 2:285 (1983)).

Plasmid vectors comprising the instant chimeric genes can then be constructed. The choice of plasmid vector depends upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different

independent transformation events will result in different levels and patterns of expression (Jones *et al.*, (1985) *EMBO J.* 4:2411-2418; De Almeida *et al.*, (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA blots (Southern, *J. Mol. Biol.* 98, 503, (1975)). Northern analysis of mRNA expression (Kroczeck, *J. Chromatogr. Biomed. Appl.*, 618 (1-2) (1993) 133-145), Western analysis of protein expression, or phenotypic analysis.

For some applications it will be useful to direct the instant proteins to different cellular compartments. It is thus envisioned that the chimeric genes described above may be further supplemented by altering the coding sequences to encode enzymes with appropriate intracellular targeting sequences such as transit sequences (Keegstra, K., *Cell* 56:247-253 (1989)), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels, J.J., *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53 (1991)), or nuclear localization signals (Raikhel, N. *Plant Phys.* 100:1627-1632 (1992)) added and/or with targeting sequences that are already present removed. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of utility may be discovered in the future that are useful in the invention.

Protein Engineering

It is contemplated that the present nucleotides may be used to produce gene products having enhanced or altered activity. Various methods are known for mutating a native gene sequence to produce a gene product with altered or enhanced activity including but not limited to error prone PCR (Melnikov *et al.*, *Nucleic Acids Research*, (February 15, 1999) Vol. 27, No. 4, pp. 1056-1062); site directed mutagenesis (Coombs *et al.*, *Proteins* (1998), 259-311, 1 plate. Editor(s): Angeletti, Ruth Hogue. Publisher: Academic, San Diego, CA) and "gene shuffling" (U.S. 5,605,793; U.S. 5,811,238; U.S. 5,830,721; and U.S. 5,837,458, incorporated herein by reference).

The method of gene shuffling is particularly attractive due to its facile implementation, and high rate of mutagenesis and ease of screening. The process of gene shuffling involves the restriction endonuclease cleavage of a gene of interest into fragments of specific size in the presence of additional populations of DNA regions of both similarity

to or difference to the gene of interest. This pool of fragments will then be denatured and reannealed to create a mutated gene. The mutated gene is then screened for altered activity.

The instant microbial sequences of the present invention may be mutated and screened for altered or enhanced activity by this method. The sequences should be double stranded and can be of various lengths ranging from 50 bp to 10 kb. The sequences may be randomly digested into fragments ranging from about 10 bp to 1000 bp, using restriction endonucleases well known in the art (*Maniatis supra*). In addition to the instant microbial sequences, populations of fragments that are hybridizable to all or portions of the microbial sequence may be added. Similarly, a population of fragments which are not hybridizable to the instant sequence may also be added. Typically these additional fragment populations are added in about a 10 to 20 fold excess by weight as compared to the total nucleic acid. Generally if this process is followed the number of different specific nucleic acid fragments in the mixture will be about 100 to about 1000. The mixed population of random nucleic acid fragments are denatured to form single-stranded nucleic acid fragments and then reannealed. Only those single-stranded nucleic acid fragments having regions of homology with other single-stranded nucleic acid fragments will reanneal. The random nucleic acid fragments may be denatured by heating. One skilled in the art could determine the conditions necessary to completely denature the double stranded nucleic acid. Preferably the temperature is from 80°C to 100°C. The nucleic acid fragments may be reannealed by cooling. Preferably the temperature is from 20°C to 75°C. Renaturation can be accelerated by the addition of polyethylene glycol ("PEG") or salt. A suitable salt concentration may range from 0 mM to 200 mM. The annealed nucleic acid fragments are then incubated in the presence of a nucleic acid polymerase and dNTP's (i.e., dATP, dCTP, dGTP and dTTP). The nucleic acid polymerase may be the Klenow fragment, the Taq polymerase or any other DNA polymerase known in the art. The polymerase may be added to the random nucleic acid fragments prior to annealing, simultaneously with annealing or after annealing. The cycle of denaturation, renaturation and incubation in the presence of polymerase is repeated for a desired number of times. Preferably the cycle is repeated from 2 to 50 times, more preferably the sequence is repeated from 10 to 40 times. The resulting nucleic acid is a larger double-stranded polynucleotide ranging from about 50 bp to about

100 kb and may be screened for expression and altered activity by standard cloning and expression protocol (Manatis *supra*).

Furthermore, a hybrid protein can be assembled by fusion of functional domains using the gene shuffling (exon shuffling) method (Nixon et al., PNAS, 94:1069-1073 (1997)). The functional domain of the instant gene can be combined with the functional domain of other genes to create novel enzymes with desired catalytic function. A hybrid enzyme may be constructed using PCR overlap extension method and cloned into the various expression vectors using the techniques well known to those skilled in art.

Gene Expression Profiling

All or portion of the nucleic acid fragments of the instant invention may also be used as probes for gene expression monitoring and gene expression profiling. Many external changes such as changes in growth condition, exposure to chemicals, can cause induction or repression of genes in the cell. The induction or repression of gene can be used for a screening system to determine the best production condition for production organism. On the other hand, by amplifying or disrupting genes, one can manipulate the production of the amount of cellular products as well as the timeline. The genes may be monitored for expression and or regulation of expression by oxygen. It may be desirable to deregulate or derepress these genes by knocking out regulatory elements or over-expressing regulatory elements in order to get the desired product or desired yield.

For example, all or a portion of the instant nucleic acid fragments may be immobilized on a nylon membrane or a glass slide. A Generation II DNA spotter (Molecular Dynamics) is one of the available technology to array the DNA samples onto the coated glass slides. Other array methods are also available and well known in the art. After the cells were grown in various growth conditions or treated with potential candidates, cellular RNA is purified. Fluorescent or radioactive labeled target cDNA can be made by reverse transcription of mRNA. The target mixture is hybridized to the probes, washed using conditions well known in the art. The amount of the target gene expression is quantified by the intensity of radioactivity or fluorescence label (e.g., confocal laser microscope: Molecular Dynamics). The intensities of radioactivity or fluorescent label at the immobilized probes are measured using the technology well known in the art. The two color fluorescence detection scheme (e.g., Cy3 and Cy5) has the advantage over radioactively labeled targets of allowing rapid and

simultaneous differential expression analysis of independent samples. In addition, the use of ratio measurements compensates for probe to probe variation of intensity due to DNA concentration and hybridization efficiency. In the case of fluorescence labeling, the two fluorescent
5 images obtained with the appropriate excitation and emission filters constitute the raw data from differential gene expression ratio values are calculated. The intensity of images are analyzed using the available software (e.g., Array Vision 4.0: Imaging Research Inc.) well known in the art and normalized to compensate for the differential efficiencies of
10 labeling and detection of the label. There are many different ways known in the art to normalize the signals. One of the ways to normalize the signal is by correcting the signal against internal controls. Another way is to run a separate array with labeled genomic driven DNA and compare the signal with mRNA driven signals. This method also allows to measure the
15 transcript abundance. The array data of individual gene is examined and evaluated to determine the induction or repression of the gene under the test condition.

Description of the Preferred Embodiments

The original environmental sample containing *Methylobacter* 16a
20 was obtained from pond sediment. The pond sediment was inoculated directly into a defined mineral medium under 25% methane in air. Methane was used as the sole source of carbon and energy. Growth was followed until the optical density at 660 nm was stable whereupon the culture was transferred to fresh medium such that a 1:100 dilution was
25 achieved. After 3 successive transfers with methane as the sole carbon and energy source, the culture was plated onto defined minimal medium agar and incubated under 25% methane in air.

The activity of the present genes and gene products has been confirmed by studies showing the increase in carotenoid production in the
30 source strain, *Methylobacter* 16a. By overexpressing genes that are early in the isoprenoid pathway, *dxr* and *dxs*, an increase in carotenoid production was observed in *Methylobacter* 16a cells. Briefly, genes *dxr* and *dxs* were overexpressed in *Methylobacter* 16a by cloning them into the low-copy, broad-host range plasmid pTJS75::lacZ:Tn5Kn
35 (Schmidhauser and Helinski, *J. Bacteriology*. Vol.164:446-455 (1985)). The method for cloning genes into the host plasmid is well known in the art. Genes were amplified from the *Methylobacter* 16a genome via PCR with the following primers.

Dxs primers

Dxs: Primer for forward reaction: aaggatccgctattcgctactc (contains a Bam HI site: SEQ ID NO:19).

Dxs: Primer for reverse reaction:

- 5 ctggatccgatctagaaataggctcgagttgtcgttcagg (contains a Bam HI and a Xho I site: SEQ ID NO:20).

Dxr primers:

Forward reaction: aaggatcctactcgagctgacatcagtgct (contains a Bam HI and a Xho I site: SEQ ID NO:21).

- 10 Reverse reaction: gctctagatgcaaccagaatcg (contains a Xba I site: SEQ ID NO:22).

- The expected PCR product of *dxs* included a 323 bp sequence upstream of the start codon and the expected PCR product of *dxr* included 420 bp sequence upstream of the start codon in order to ensure that the natural promoters of the genes were present. First, the *dxs* gene was cloned into the Bam HI site, which was located between the *lacZ* gene and the Tn5Kn cassette of pTJS75::lacZ:Tn5Kn. The resulting plasmids were isolated from *E. coli* transformants growing on LB with kanamycin (50 µg/mL). The plasmid containing the insert in the direction of the Kn-resistance gene (as confirmed by restriction analysis) was chosen for further cloning. The *dxr* gene was cloned in between *dxs* and the Tn5Kn cassette using the Xho I and Xba I sites. The resulting plasmid is shown in Figure 3b. The plasmid was transformed into *E. coli* using electroporation methods well known in the art. The presence of *dxs* and *dxr* in the plasmid was confirmed by restriction analysis and sequencing.

- The plasmid pTJS75::dxs:dxr:lacZ:Tn5Kn was transferred from *E. coli* into *Methylobacter* 16a by triparental conjugation methods well known in the art (Rainey et al., *Mol. Gen. Genet.* (1997), 256(1), 84-87). A spontaneous rifampin (Rif)-resistant isolate of strain *Methylobacter* 16a was used as the recipient to speed the isolation of the methanotroph from contaminating *E. coli* following the mating. *E. coli* harboring the pTJS75::dxs:dxr:lacZ:Tn5Kn plasmid was the donor and *E. coli* harboring plasmid pRK2013 (Figurski and Helinski; *Proc. Natl. Acad. Sci. U.S.A.* 76:1648-1652(1979)) served as the helper. Six separately isolated kanamycin-resistant *Methylobacter* 16a transconjugants were isolated and used for the carotenoid content determination. The wild type stain and Rif resistant derivative without plasmid were used as negative controls. Six transconjugants were tested for carotenoid concentration. During the

extraction, pink coloration was observed in the supernatant. The cellular carotenoid was analyzed spectrophotometrically. No qualitative differences were noticed in the spectra between negative controls and transconjugants. There were no quantitative differences between the four negative controls. There were no quantitative differences between the six transconjugants. Transconjugants have approximately a 28% increase in carotenoid concentration when compared to the negative controls (Table 3). The overproduction of *dxr* and *dxs* genes in the transconjugants is assumed to be the cause of the increase in the carotenoid production in the transconjugants. Carotenoid produced in the *Methylomonas* cells were similar in structure as in the reference strain *Methylobacterium rhodinum* as seen in HPCL analysis of saponified extract.

EXAMPLES

The present invention is further defined in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

GENERAL METHODS

Standard recombinant DNA and molecular cloning techniques used in the Examples are well known in the art and are described by Sambrook, J., Fritsch, E. F. and Maniatis, T. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, (1989) (Maniatis) and by T. J. Silhavy, M. L. Bannan, and L. W. Enquist, *Experiments with Gene Fusions*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and by Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, pub. by Greene Publishing Assoc. and Wiley-Interscience (1987).

Materials and methods suitable for the maintenance and growth of bacterial cultures are well known in the art. Techniques suitable for use in the following examples may be found as set out in Manual of Methods for General Bacteriology (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds), American Society for Microbiology, Washington, DC. (1994))

or by Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition, Sinauer Associates, Inc., Sunderland, MA (1989). All reagents, restriction enzymes and materials used for the growth and maintenance of bacterial cells were obtained from Aldrich Chemicals (Milwaukee, WI), DIFCO Laboratories (Detroit, MI), GIBCO/BRL (Gaithersburg, MD), or Sigma Chemical Company (St. Louis, MO) unless otherwise specified.

Manipulations of genetic sequences were accomplished using the suite of programs available from the Genetics Computer Group Inc. (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, WI). Where the GCG program "Pileup" was used the gap creation default value of 12, and the gap extension default value of 4 were used. Where the CGC "Gap" or "Bestfit" programs were used the default gap creation penalty of 50 and the default gap extension penalty of 3 were used. Multiple alignments were created using the FASTA program incorporating the Smith-Waterman algorithm (W. R. Pearson, *Comput. Methods Genome Res.*, [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Publisher: Plenum, New York, NY). In any case where program parameters were not prompted for, in these or any other programs, default values were used.

The meaning of abbreviations is as follows: "h" means hour(s), "min" means minute(s), "sec" means second(s), "d" means day(s), "mL" means milliliters, "L" means liters.

EXAMPLE 1

Isolation Of *Methylobacter* 16a

The original environmental sample containing the isolate was obtained from pond sediment. The pond sediment was inoculated directly into growth medium with ammonium as nitrogen source under 25% methane in air. Methane was the sole source of carbon and energy. Growth was followed until the optical density at 660 nm was stable whereupon the culture was transferred to fresh medium such that a 1:100 dilution was achieved. After 3 successive transfers with methane as sole carbon and energy source the culture was plated onto growth agar with ammonium as nitrogen source and incubated under 25% methane in air. Many methanotrophic bacterial species were isolated in this manner. However, *Methylobacter* 16a was selected as the organism to study due to the rapid growth of colonies, large colony size, ability to grow on minimal

media, and pink pigmentation indicative of an active biosynthetic pathway for carotenoids.

EXAMPLE 2

Preparation of Genomic DNA for Sequencing and Sequence Generation

5 Genomic DNA was isolated from *Methylomonas* according to standard protocols.

 Genomic DNA and library construction were prepared according to published protocols (Friseur et al., The Minimal Gene Complement of *Mycoplasma genitalium*; Science 270, 1995). A cell pellet was
10 resuspended in a solution containing 100 mM Na-EDTA pH 8.0, 10 mM tris-HCl pH 8.0, 400 mM NaCl, and 50 mM MgCl₂.

Genomic DNA preparation. After resuspension, the cells were gently lysed in 10% SDS, and incubated for 30 min at 55°C. After incubation at room temperature, proteinase K was added to 100 µg/mL
15 and incubated at 37°C until the suspension was clear. DNA was extracted twice with tris-equilibrated phenol and twice with chloroform. DNA was precipitated in 70% ethanol and resuspended in a solution containing 10 mM tris-HCl and 1 mM Na-EDTA (TE) pH 7.5. The DNA solution was treated with a mix of RNAases, then extracted twice with tris-equilibrated
20 phenol and twice with chloroform. This was followed by precipitation in ethanol and resuspension in TE.

Library construction. 200 to 500 µg of chromosomal DNA was resuspended in a solution of 300 mM sodium acetate, 10 mM tris-HCl, 1 mM Na-EDTA, and 30% glycerol, and sheared at 12 psi for 60 sec in an
25 Aeromist Downdraft Nebulizer chamber (IBI Medical products, Chicago, IL). The DNA was precipitated, resuspended and treated with Bal31 nuclease. After size fractionation, a fraction (2.0 kb, or 5.0 kb) was excised, cleaned and a two-step ligation procedure was used to produce a high titer library with greater than 99% single inserts.

30 Sequencing. A shotgun sequencing strategy approach was adopted for the sequencing of the whole microbial genome (Fleischmann, Robert et al., Whole-Genome Random sequencing and assembly of *Haemophilus influenzae* Rd Science, 269:1995).

 Sequence was generated on an ABI Automatic sequencer using
35 dye terminator technology (U.S. 5366860; EP 272007) using a combination of vector and insert-specific primers. Sequence editing was performed in either DNASTar (DNA Star Inc.) or the Wisconsin GCG program (Wisconsin Package Version 9.0, Genetics Computer Group

(GCG), Madison, WI) and the CONSED package (version 7.0). All sequences represent coverage at least two times in both directions.

EXAMPLE 3

Identification and Characterization of Bacterial ORF's

5 ORFs encoding 1-9 were initially identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant (nr) GenBank CDS translations, sequences derived from
10 the 3-dimensional structure Brookhaven Protein Data Bank, the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The sequences obtained in Example 2 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology
15 Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTP algorithm (Altschul, S. F., et al., *Nucleic Acid Res.* 25:3389-3402) (1997) provided by the NCBI.

20 All initial comparisons were done using either the BLASTNnr or BLASTPnr algorithm. A refined similarity search was performed using FASTA (version 3.2) with the default parameters settings (BLOSUM 50 scoring matrix, word size ktup = 2, gap penalty = -12 for the first residue and -2 for every additional residue in the gap). The results of the FASTA
25 comparison is given in Table 1 which summarize the sequences to which they have the most similarity. Table 1 displays data based on the FASTA algorithm with values reported in expect values. The Expect value estimates the statistical significance of the match, specifying the number of matches, with a given score, that are expected in a search of a database
30 of this size absolutely by chance.

 A gene cluster of *ispD*, *ispF* and *pyrG* and another gene cluster of genes *crtN1* and *crtN2* are shown in Figure 2.

Table 1

ORF Name	Gene Name	Similarity Identified	SEQID	SEQID peptide	% Identity ^a	% Similarity ^b	E-value ^c	Citation
1	<i>dxs</i>	1-deoxyxylulose-5-phosphate synthase (<i>E. coli</i>)	1	2	60%	86%	5.7e-149	Lois et al., <i>Proc. Natl. Acad. Sci. USA</i> 95 (5), 2105-2110 (1998)
2	<i>dxr</i>	1-deoxy-d-xylulose 5-phosphate reductoisomerase (<i>E. coli</i>)	3	4	55%	78%	3.3e-74	Takahashi et al., <i>Proc. Natl. Acad. Sci. USA</i> 95:9879-9884 (1998)
3	<i>ygbP/ispD</i>	2C-methyl-d-erythritol cytidyltransferase (<i>E. coli</i>)	5	6	52%	74%	7.7e-36	Rohdich et al., <i>Proc. Natl. Acad. Sci. USA</i> 1999 Oct 12;96(21):11758-63
4	<i>ygbB/ispE</i>	4-diphosphocytidyl-2-C-methylethylthritol kinase (<i>E. coli</i>)	7	8	50%	73%	8.8e-49	Lüttgen et al., <i>Proc. Natl. Acad. Sci. USA</i> 2000 Feb 1;97(3):1062-7.
5	<i>ygbB/ispF</i>	2C-methyl-d-erythritol 2,4-cyclodiphosphate synthase (<i>E. coli</i>)	9	10	69%	84%	1.6e-36	Herz et al., <i>Proc. Natl. Acad. Sci. U S A</i> 2000 Mar 14;97(6):2486-90
6	<i>pyrG</i>	CTP synthase (<i>E. coli</i>)	11	12	67%	89%	2.4e-141	Weng. et al., <i>J. Biol. Chem.</i> 261:5568-5574 (1986)
7	<i>lspA</i>	Geranyltranstransferase (also farnesyl-diphosphate synthase) (<i>Synechococcus elongatus</i>)	13	14	57%	78%	7.8e-56	Ohto, et al., <i>Plant Mol. Biol.</i> 40 (2), 307-321 (1999)
8	<i>crtN1</i>	diapophytoene dehydrogenase CrtN—copy 1 (<i>Helicobacter mobilis</i>)	15	16	34%	72%	4e-66	Xiong, et al., <i>Proc. Natl. Acad. Sci. U.S.A.</i> 95 (25), 14851-14856 (1998)

ORF Name	Gene Name	Similarity Identified	SEQID	SEQID peptide	% Identity ^a	% Similarity ^b	E-value ^c	Citation
9	<i>crfN2</i>	Diapophytoene dehydrogenase CrfN— copy 2 (<i>Staphylococcus aureus</i>)	17	18	49%	78%	1.3e-76	Genbank # : X97985
10	<i>lytB</i>	Acinetobacter sp BD413 Putative penicillin binding protein*	23	24	65	87	3.4e-75	Genbank# G.I. 5915671

^a%Identity is defined as percentage of amino acids that are identical between the two proteins.

^b% Similarity is defined as percentage of amino acids that are identical or conserved between the two proteins.

^cExpect value. The Expect value estimates the statistical significance of the match, specifying the number of matches, with a given score, that are expected in a search of a database of this size absolutely by chance.

% Identity, % similarity, and e-values are all reported according to FASTA analysis with Smith-Waterman computation.

* Gene function determined to be in the generation of IPP dimethylallyl diphosphate

EXAMPLE 4Up Regulation of *dxs* and *dxr* genes

For the cloning, the low-copy, broad-host plasmid, pTJS75::lacZ:Tn5Kn was used (Schmidhauser and Helinski *J.*

- 5 *Bacteriology*. Vol.164:446-455 (1985). Genes *dxs* and *dxr* were amplified from the *Methylomonas* 16a genome by using PCR with the following primers.

Dxs primers:

- Forward reaction: aaggatccgcgtattcgtagtc (contains a Bam HI site,
10 SEQ ID NO:19).

Reverse reaction: ctggatccgatctagaaataggctcgagttgtcgttcagg
(contains a Bam HI and a Xho I site, SEQ ID NO:20).

Dxr primers:

- Forward reaction: aaggatcctactcgagctgacatcagtgtc (contains a Bam
15 HI and a Xho I site, SEQ ID NO:21).

Reverse reaction: gctctagatgcaaccagaatcg (contains a Xba I site,
SEQ ID NO:22).

- The expected PCR products of *dxs* and *dxr* genes included
sequences of 323 bp and 420 bp, respectively, upstream of the start
20 codon of each gene in order to ensure that the natural promoters of the
genes were present.

PCR program (in Perkin-Elmer, Norwalk, CT):

- Activation: 95°C - 900sec
Cycle (35 times): 94°C - 45sec
25 58°C - 45sec
72°C - 60sec
Final elongation: 72°C - 600sec

PCR Reaction mixture:

- 25 µl Hot Star master mix (Qiagen, Valencia, CA)
30 0.75 µl genomic DNA (approx. 0.1 ng)
1.2 µl sense primer (=10 pmol)
1.2 µl antisense primer (=10 pmol)
21.85 µl deionized water
50 µl

- 35 Standard procedures (Sambrook, J., Fritsch, E. F. and Maniatis, T.
Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring

Harbor Laboratory Press, Cold Spring Harbor (1989)), were used in order to clone *dxs* and *dxr* into pTJS75::lacZ:Tn5Kn:

- For isolation, concentration, and purification of DNA, Qiagen kits (Valencia, CA) were used. Enzymes for the cloning were purchased from
 5 Gibco/BRL (Rockville, MD) or NEB (Beverly, MA). To transfer plasmids into *E. coli*, One Shot Top10 competent cells (Invitrogen, Carlsbad, CA), cuvettes (0.2 cm; Invitrogen), and Bio-Rad Gene Pulser III (Hercules, CA) with standard settings were used for electroporation.

10

Table 2: BTZ medium for *Methylobacterium* 16a

Composition:

	MW	Conc. (mM)	g per L
NaNO ₃	84.99	10	0.85
KH ₂ PO ₄	136.09	3.67	0.5
Na ₂ SO ₄	142.04	3.52	0.5
MgCl ₂ x 6H ₂ O	203.3	0.98	0.2
CaCl ₂ x 2H ₂ O	147.02	0.68	0.1
1 M HEPES (pH 7)	238.3		50 mL
Solution 1			10 mL

Solution 1 (metal solution)

15

	MW	Conc. (mM)	g per L
Nitriloacetic acid	191.1	66.9	12.8
CuCl ₂ x 2H ₂ O	170.48	0.15	0.0254
FeCl ₂ x 4H ₂ O	198.81	1.5	0.3
MnCl ₂ x 4H ₂ O	197.91	0.5	0.1
CoCl ₂ x 6H ₂ O	237.9	1.31	0.312
ZnCl ₂	136.29	0.73	0.1
H ₃ BO ₃	61.83	0.16	0.01
Na ₂ MoO ₄ x 2H ₂ O	241.95	0.04	0.01
NiCl ₂ x 6H ₂ O	237.7	0.77	0.184

First, *dxs* was cloned into the Bam HI site, which was located between the *lacZ* gene and the Tn5Kn cassette of pTJS75::lacZ:Tn5Kn. The resulting plasmids were isolated from *E. coli* transformants growing on LB+ kanamycin (Kn, 50 µg/mL). The plasmid containing the insert in
 5 direction of the Kn-resistance gene (as confirmed by restriction analysis) was chosen for further cloning. Dxr gene was cloned in between *dxs* and Tn5Kn cassette by using the Xho I and Xba I sites. The anticipated plasmid was isolated from *E. coli* transformants. The presence of *dxs* and *dxr* in the plasmid was confirmed by restriction analysis and sequencing.
 10 The resulting plasmid, pTJS75::dxs:dxr:lacZ:Tn5Kn is shown in Figure 3b.
16a transconjugants

The plasmid pTJS75::dxs:dxr:lacZ:Tn5Kn was transferred from *E. coli* into *Methylobacter* 16a by triparental conjugation well known in the art (Rainey et al., *Mol. Gen. Genet.* (1997), 256(1), 84-87).
 15 A spontaneous rifampin (Rif)-resistant isolate of strain *Methylobacter* 16a was used as the recipient to speed the isolation of the methanotroph from contaminating *E. coli* following the mating. *E. coli* harboring the pTJS75::dxs:dxr:lacZ:Tn5Kn plasmid was the donor and *E. coli* harboring plasmid pRK2013 (Figurski and Helinski; *Proc. Natl. Acad. Sci. U.S.A.* 76:1648-1652(1979)) served as the helper. The
 20 approximate relative cell concentrations on the plates were recipient:donor:helper= 2:1:1

The corresponding LB plates were incubated under methane (25%) at 30°C overnight. Then the mating mixtures were scraped off the plates, resuspended in 1 mL of BTZ medium (Table 2), and plated onto BTZ
 25 plates supplemented with Rif (25 µg/mL) and Kn (50 µg/mL). The plates were incubated under methane (25%) for 7 days at 30°C to select for *Methylobacter* 16a transconjugants. Upcoming colonies were picked and transferred to fresh selection plates for further purification. Six separately
 30 isolated kanamycin-resistant *Methylobacter* 16a transconjugants were used for carotenoid content determination.

For carotenoid determination, six 100 mL cultures of transconjugants (in BTZ + 50 µg/mL Kn) were grown under methane (25%) over the weekend to stationary growth phase. Two cultures of
 35 each, the wild-type strain and its Rif-resistant derivative without the plasmid, served as a control to see whether there are different carotenoid contents in those strains and to get a standard deviation of the carotenoid

determination. Cells were spun down, washed with distilled water, and freeze-dried (lyophilizer: Virtis, Gardiner, NY) for 24 h in order to determine dry-weights. After the dry-weight of each culture, was determined, cells were extracted. First, cells were welled with 0.4 mL of water and let stand
5 for 15 min. After 15 min, four mL of acetone was added and thoroughly vortexed to homogenize the sample. The samples were then shaken at 30°C for 1 hr. After 1 hr, the cells were centrifuged. Pink coloration was observed in the supernatant. The supernatant was collected and pellets were extracted again with 0.3 mL of water and 3 mL of acetone. The
10 supernatants from the second extraction were lighter pink in color. The supernatants of both extractions were combined, their volumes were measured, and analyzed spectrophotometrically. No qualitative differences were seen in the spectra between negative control and transconjugant samples. In acetone extract, a following observation was
15 typical measured by spectrophotometer (shoulder at 460 nm, maxima at 491 and 522 nm) (Amersham Pharmacia Biotech, Piscataway, NJ). For calculation of the carotenoid content, the absorption at 491 nm was read, the molar extinction coefficient of bacterioruberin (188,000) and a MW of 552 were used. The MW of the carotenoid (552 g/mol) was determined by
20 MALDI-MS of a purified sample (Silica/Mg adsorption followed by Silica column chromatography, reference: Britton, G., Liaaen-Jensen, S., Pfander, H., Carotenoids Vol. 1a; Isolation and analysis, Birkhäuser Verlag, Basel, Boston, Berlin (1995)).

A crude acetone extract from *Methylobacterium 16a* cells has a typical
25 absorption spectrum (inflexion at 460 nm, maxima at 491 nm and 522 nm). HPLC analysis (Beckman Gold Nouveau System, Columbia, MD; Conditions: 125 x 4 mm RP8 (5 µm particles) column with corresponding guard column (Hewlett-Packard, San Fernando, CA); flow 1 mL/min; solvent program: 0-10 min 15% water/85% methanol, then 100%
30 methanol) of acetone extracts confirmed that one major carotenoid (net retention volume at about 6 mL) with above mentioned absorption spectrum is responsible for the pink coloration of wild-type and transconjugant *Methylobacterium 16a* cells. Because nothing else in the extract absorbs at 491 nm, carotenoid content was directly measured in
35 the acetone extract with a spectrophotometer (Amersham Pharmacia Biotech, Piscataway, NJ).

The molar extinction coefficient of bacterioruberin (188,000), was used for the calculation of the quantity.

The following formula was used (Lambert-Beer's law) to determine the quantity of carotenoid:

5

$$Ca = A_{491nm} / (d \times \epsilon \times v \times MW)$$

Ca: Carotenoid amount (g)

A_{491nm} : Absorption of acetone extract at 491 nm (-)

d: Light path in cuvette (1 cm)

10

ϵ : Molar extinction coefficient (L/(mol x cm))

MW: Molecular weight (g/mol)

v: Volume of extract (L)

15 To get the carotenoid content, the calculated carotenoid amount has to be divided by the corresponding cell dry weight.

Table 3. Carotenoid contents in *Methylomonas* 16a cells

Cultures	dry weight (mg)	carotenoid (g)	carotenoid content (µg/g)
16a-1 ^a	30.8	3.00194E-06	97.5
16a-2 ^a	30.8	3.0865E-06	100.2
16a Rif-1 ^b	29.2	3.12937E-06	107.2
16a Rif-2 ^b	30.1	3.02014E-06	100.3
dxp 1 ^c	28.2	3.48817E-06	123.7
dxp 2 ^c	23.8	3.17224E-06	133.3
dxp 3 ^c	31.6	4.01962E-06	127.2
dxp 4 ^c	31.8	4.38899E-06	138.0
dxp 5 ^c	28.4	3.4547E-06	121.6
dxp 6 ^c	30.3	4.00817E-06	132.3

20 a: *Methylomonas* 16a native strain
 b: Rif resistant derivative of *Methylomonas* 16a without plasmid
 c: transconjugants containing pTJS75::dxs:dxr:lacZ:Tn5Kn plasmid

25 There were no significant differences between four negative controls. Likewise, there were no significant differences between six transconjugants. However, approximately 28% increase in average carotenoid production was observed in the transconjugants in comparison to the average carotenoid production in negative controls (Table 3).

In order to confirm the structure, *Methylobacterium rhodinum* (formerly *Pseudomonas rhodos*: ATCC No. 14821) of which C30-

carotenoid was identified was used as a reference strain (Kleinig *et al.*, Z. Naturforsch 34c, 181-185 (1979); Kleinig and Schmitt, Z. Naturforsch 37c, 758-760 (1982)). A saponified extract of *Methylobacterium rhodinum* and of *Methylomonas 16a* were compared by HPLC analysis under the same

5 conditions as mentioned above. The results are shown as follows:

Saponified *M. rhodinum*: inflexion at 460 nm, maxima at 487 nm, 517 nm.

Net retention volume=1.9 mL.

Saponified *Methylomonas 16a*: inflexion at 460 nm, maxima at 488 nm, 518 nm.

10

Net retention volume= 2.0 mL.

CLAIMS

What is claimed is:

1. An isolated nucleic acid molecule encoding a isoprenoid biosynthetic enzyme, selected from the group consisting of:
 - 5 (a) an isolated nucleic acid molecule encoding the amino acid sequence selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18 and 24;
 - (b) an isolated nucleic acid molecule that hybridizes with (a) under the following hybridization conditions: 0.1X SSC, 0.1% SDS, 65°C and washed with 2X SSC, 0.1% SDS
10 followed by 0.1X SSC, 0.1% SDS; and
 - (c) an isolated nucleic acid molecule that is complementary to (a) or (b).
2. The isolated nucleic acid molecule of Claim 1 selected from the
15 group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17 and 23.
3. A polypeptide encoded by the isolated nucleic acid molecule of Claim 1.
4. The polypeptide of Claim 3 selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, and 18.
- 20 5. An isolated nucleic acid molecule comprising a first nucleotide sequence encoding a polypeptide of at least 620 amino acids that has at least 60% identity based on the Smith-Waterman method of alignment when compared to a polypeptide having the sequence as set forth in SEQ ID NO:2 or a second nucleotide sequence comprising the complement of
25 the first nucleotide sequence.
6. An isolated nucleic acid molecule comprising a first nucleotide sequence encoding a polypeptide of at least 394 amino acids that has at least 55% identity based on the Smith-Waterman method of alignment when compared to a polypeptide having the sequence as set forth in SEQ
30 ID NO:4 or a second nucleotide sequence comprising the complement of the first nucleotide sequence.
7. An isolated nucleic acid molecule comprising a first nucleotide sequence encoding a polypeptide of at least 231 amino acids that has at least 52% identity based on the Smith-Waterman method of alignment
35 when compared to a polypeptide having the sequence as set forth in SEQ ID NO:6 or a second nucleotide sequence comprising the complement of the first nucleotide sequence.

8. An isolated nucleic acid molecule comprising a first nucleotide sequence encoding a polypeptide of at least 285 amino acids that has at least 50% identity based on the Smith-Waterman method of alignment when compared to a polypeptide having the sequence as set forth in SEQ ID NO:8 or a second nucleotide sequence comprising the complement of the first nucleotide sequence.

9. An isolated nucleic acid molecule comprising a first nucleotide sequence encoding a polypeptide of at least 157 amino acids that has at least 69% identity based on the Smith-Waterman method of alignment when compared to a polypeptide having the sequence as set forth in SEQ ID NO:10 or a second nucleotide sequence comprising the complement of the first nucleotide sequence.

10. An isolated nucleic acid molecule comprising a first nucleotide sequence encoding a polypeptide of at least 544 amino acids that has at least 67% identity based on the Smith-Waterman method of alignment when compared to a polypeptide having the sequence as set forth in SEQ ID NO:12 or a second nucleotide sequence comprising the complement of the first nucleotide sequence.

11. An isolated nucleic acid molecule comprising a first nucleotide sequence encoding a polypeptide of at least 297 amino acids that has at least 57% identity based on the Smith-Waterman method of alignment when compared to a polypeptide having the sequence as set forth in SEQ ID NO:14 or a second nucleotide sequence comprising the complement of the first nucleotide sequence.

12. An isolated nucleic acid molecule comprising a first nucleotide sequence encoding a polypeptide of at least 511 amino acids that has at least 34% identity based on the Smith-Waterman method of alignment when compared to a polypeptide having the sequence as set forth in SEQ ID NO:16 or a second nucleotide sequence comprising the complement of the first nucleotide sequence.

13. An isolated nucleic acid molecule comprising a first nucleotide sequence encoding a polypeptide of at least 497 amino acids that has at least 49% identity based on the Smith-Waterman method of alignment when compared to a polypeptide having the sequence as set forth in SEQ ID NO:18 or a second nucleotide sequence comprising the complement of the first nucleotide sequence.

14. An isolated nucleic acid molecule comprising a first nucleotide sequence encoding a polypeptide of at least 318 amino acids that has at least 65% identity based on the Smith-Waterman method of alignment when compared to a polypeptide having the sequence as set forth in SEQ ID NO:24 or a second nucleotide sequence comprising the complement of the first nucleotide sequence.

15. A chimeric gene comprising the isolated nucleic acid molecule of any one of Claims 1 or 5-14 operably linked to suitable regulatory sequences.

16. A transformed host cell comprising the chimeric gene of Claim 15.

17. The transformed host cell of Claim 16 wherein the host cell is selected from the group consisting of bacteria, yeast, filamentous fungi, and green plants.

18. The transformed host cell of Claim 17 wherein the host cell is selected from the group consisting of *Aspergillus*, *Trichoderma*, *Saccharomyces*, *Pichia*, *Candida*, *Hansenula*, *Salmonella*, *Bacillus*, *Acinetobacter*, *Rhodococcus*, *Streptomyces*, *Escherichia*, *Pseudomonas*, *Methylobacter*, *Alcaligenes*, *Synechocystis*, *Anabaena*, *Thiobacillus*, *Methanobacterium* and *Klebsiella*.

19. The transformed host cell of Claim 17 wherein the host cell is selected from the group consisting of soybean, rapeseed, sunflower, cotton, corn, tobacco, alfalfa, wheat, barley, oats, sorghum, rice, *Arabidopsis*, cruciferous vegetables, melons, carrots, celery, parsley, tomatoes, potatoes, strawberries, peanuts, grapes, grass seed crops, sugar beets, sugar cane, beans, peas, rye, flax, hardwood trees, softwood trees, and forage grasses.

20. A method of obtaining a nucleic acid molecule encoding an isoprenoid compound biosynthetic enzyme comprising:

- (a) probing a genomic library with the nucleic acid molecule of any one of Claims 1 or 5-14;
- (b) identifying a DNA clone that hybridizes with the nucleic acid molecule of any one of Claims 1 or 5-14; and
- (c) sequencing the genomic fragment that comprises the clone identified in step (b),

wherein the sequenced genomic fragment encodes an isoprenoid biosynthetic enzyme.

21. A method of obtaining a nucleic acid molecule encoding an isoprenoid biosynthetic enzyme comprising:

- 5 (a) synthesizing an at least one oligonucleotide primer corresponding to a portion of the sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17 and 23; and
- (b) amplifying an insert present in a cloning vector using the oligonucleotide primer of step (a);

10 wherein the amplified insert encodes a portion of an amino acid sequence encoding an isoprenoid biosynthetic enzyme.

22. The product of the method of Claims 20 or 21.

23. A method for the production of isoprenoid compounds comprising: contacting a transformed host cell under suitable growth conditions with an effective amount of a carbon source whereby an isoprenoid compound is produced, said transformed host cell comprising a set of nucleic acid molecules encoding SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18 and 24 under the control of suitable regulatory sequences.

24. A method according to Claim 23 wherein the transformed host cell is selected from the group consisting of *Aspergillus*, *Trichoderma*, 20 *Saccharomyces*, *Pichia*, *Candida*, *Hansenula*, *Salmonella*, *Bacillus*, *Acinetobacter*, *Rhodococcus*, *Streptomyces*, *Escherichia*, *Pseudomonas*, *Methylomonas*, *Methylobacter*, *Alcaligenes*, *Synechocystis*, *Anabaena*, *Thiobacillus*, *Methanobacterium* and *Klebsiella*.

25. A method according to Claim 23 wherein said methanotrophic bacteria:

- 25 (a) grows on a C1 carbon substrate selected from the group consisting of methane and methanol; and
- (b) comprises a functional Embden-Meyerof carbon pathway, said pathway comprising a gene encoding a pyrophosphate dependent phosphofructokinase enzyme.

26. A method according to Claim 25 wherein said methanotrophic bacteria is *methylomonas* 16a ATCC PTA 2402.

27. A method according to Claim 23 wherein the transformed host cell is selected from the group consisting of soybean, rapeseed, sunflower, 35 cotton, corn, tobacco, alfalfa, wheat, barley, oats, sorghum, rice, *Arabidopsis*, cruciferous vegetables, melons, carrots, celery, parsley, tomatoes, potatoes, strawberries, peanuts, grapes, grass seed crops,

sugar beets, sugar cane, beans, peas, rye, flax, hardwood trees, softwood trees, and forage grasses.

28. A method according to Claim 23 wherein the carbon source is selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, carbon dioxide, methanol, methane, formaldehyde, formate, and carbon-containing amines.

29. A method according to Claim 23 wherein the transformed host is selected from the group consisting of *Methylobacter*, *Methylobacter* and *Methanobacterium* and the carbon source is selected from the group consisting of methane and methanol.

30. A method of regulating isoprenoid biosynthesis in an organism comprising, over-expressing at least one isoprenoid gene selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17 and 23 in an organism such that the isoprenoid biosynthesis is altered in the organism.

31. A method according to Claim 30 wherein said isoprenoid gene is over-expressed on a multicopy plasmid.

32. A method according to Claim 30 wherein said isoprenoid gene is operably linked to an inducible or regulated promoter.

33. A method according to Claim 30 wherein said isoprenoid gene is expressed in antisense orientation.

34. A method according to Claim 30 wherein said isoprenoid gene is disrupted by insertion of foreign DNA into the coding region.

35. A mutated gene encoding a isoprenoid enzyme having an altered biological activity produced by a method comprising the steps of:

(i) digesting a mixture of nucleotide sequences with restriction endonucleases wherein said mixture comprises:

- a) a native isoprenoid gene;
- b) a first population of nucleotide fragments which will hybridize to said native isoprenoid gene;
- c) a second population of nucleotide fragments which will not hybridize to said native isoprenoid gene;

wherein a mixture of restriction fragments are produced;

- (ii) denaturing said mixture of restriction fragments;
- (iii) incubating the denatured said mixture of restriction fragments of step (ii) with a polymerase;

- (iv) repeating steps (ii) and (iii) wherein a mutated isoprenoid gene is produced encoding a protein having an altered biological activity.

FIGURE 1





FIGURE 2

Gene Dose Effect on Carotenoid Biosynthesis




FIGURE 3a




FIGURE 3b

SEQUENCE LISTING

<110> E.I. du Pont de Nemours and Company

<120> Genes Involved in Isoprenoid Compounds Production

<130> CL1646

<140>

<141>

<150> 60/229,907

<151> September 1, 2001

<160> 24

<170> Microsoft Office 97

<210> 1

<211> 1860

<212> DNA

<213> Methylobionas 16a

<220>

<223> ORF1

<400> 1

atgaaactga	ccaccgacta	tcccttgctt	aaaaacatcc	acacgccggc	ggacatacgc	60
gcgctgtcca	aggaccagct	ccagcaactg	gctgacgagg	tgcgcgggcta	tctgaccac	120
acgggtcagca	tttccggcgg	ccattttgcg	gccggcctcg	gcaccgtgga	actgaccgtg	180
gccttgcat	atgtgttcaa	taccccgctc	gatcagttgg	tctgggacgt	gggccatcag	240
gcctatccgc	acaagattct	gaccggtcgc	aaggagcgca	tgccgaccat	tcgcaccctg	300
ggcgggggtgt	cagcctttcc	ggcgcggggac	gagagcgaat	acgatgcctt	cggcgctcggc	360
cattccagca	cctcgatcag	cgcggcactg	ggcatggcca	ttgcgtcgca	gctgcgcggc	420
gaagacaaga	agatggtagc	catcatcggc	gacggttcca	tcaccggcgg	catggcctat	480
gaggcgatga	atcatgccgg	cgatgtgaat	gccaacctgc	tggatgatctt	gaacgacaac	540
gatattgtcga	tctcgccgcc	ggtcgggggcg	atgaacaatt	atctgacca	ggtgttgtcg	600
agcaagtttt	attcgtcggg	gcgggaagag	agcaagaaag	ctctggccaa	gatgccgtcg	660
gtgtgggaac	tggcgcgcaa	gaccgaggaa	cacgtgaagg	gcattgatcgt	gcccggtagc	720
ttgttcgagg	aattgggctt	caattatttc	ggcccgatcg	acggccatga	tgtcgagatg	780
ctgggtgtcga	ccctggaaaa	tctgaaggat	ttgaccgggc	cggtattcct	gcattgtggtg	840
accaagaagg	gcaaaggcta	tgcgccagcc	gagaaagacc	cgttggccta	ccattggcgtg	900
ccggcttttcg	atccgacca	ggatttcctg	cccaaggcgg	cgccgtcgcc	gcattccgacc	960
tataccgagg	tggttcggccg	ctggctgtgc	gacatggcgg	ctcaagacga	gcgcttgctg	1020
ggcatcacgc	cggcgatgcg	cgaaggctct	ggtttggtgg	aattctcaca	gaaatttcg	1080
aatcgctatt	tcgatgtcgc	catcgccgag	cagcatgcgg	tgaccttggc	cgccggccag	1140
gcctgccagg	gcgccaagcc	ggtggtggcg	atttattcca	ccttcctgca	acgcggttac	1200
gatcagttga	tccacgacgt	ggccttgacg	aacttagata	tgtcttttgc	actggatcgt	1260
gccggcttgg	tcggcccggg	tggaccgacc	catgctggcg	cctttgatta	cagctacatg	1320
cgctgtattc	cgaacatgct	gatcatggct	ccagccgacg	agaacgagtg	caggcagatg	1380
ctgaccaccg	gcttccaaca	ccatggcccg	gcttcgggtg	gctatcccg	cggcaaagg	1440
cccggggcgg	caatcgatcc	gacctgacc	gcgctggaga	tcggcaaggc	cgaagtcaga	1500
caccacggca	gccgcacgc	cattctggcc	tggggcagca	tggtcacgcc	tgccgtcgaa	1560
gccggcaagc	agctggggcg	gacggtggtg	aacatgcgtt	tcgtcaagcc	gttcgatcaa	1620
gccttggtgc	tgggaattggc	caggacgcac	gatgtgttcg	tcaccgtcga	ggaaaacgtc	1680
atcgccggcg	gcgctggcag	tgcgatcaac	accttcctgc	aggcgcagaa	ggtgctgatg	1740
ccggtctgca	acatcggcct	gcccagaccg	ttcgtcgagc	aaggtagtcg	cgaggaattg	1800
ctcagcctgg	tcggcctcga	cagcaagggc	atcctcgcca	ccatcgaaca	gttttgcgct	1860

<210> 2
 <211> 620
 <212> PRT
 <213> Methylomonas 16a

<220>

<223> Amino acid sequences encoded by ORF1

<400> 2

```

Met Lys Leu Thr Thr Asp Tyr Pro Leu Leu Lys Asn Ile His Thr Pro
 1          5          10          15

Ala Asp Ile Arg Ala Leu Ser Lys Asp Gln Leu Gln Gln Leu Ala Asp
 20          25          30

Glu Val Arg Gly Tyr Leu Thr His Thr Val Ser Ile Ser Gly Gly His
 35          40          45

Phe Ala Ala Gly Leu Gly Thr Val Glu Leu Thr Val Ala Leu His Tyr
 50          55          60

Val Phe Asn Thr Pro Val Asp Gln Leu Val Trp Asp Val Gly His Gln
 65          70          75          80

Ala Tyr Pro His Lys Ile Leu Thr Gly Arg Lys Glu Arg Met Pro Thr
 85          90          95

Ile Arg Thr Leu Gly Gly Val Ser Ala Phe Pro Ala Arg Asp Glu Ser
100          105          110

Glu Tyr Asp Ala Phe Gly Val Gly His Ser Ser Thr Ser Ile Ser Ala
115          120          125

Ala Leu Gly Met Ala Ile Ala Ser Gln Leu Arg Gly Glu Asp Lys Lys
130          135          140

Met Val Ala Ile Ile Gly Asp Gly Ser Ile Thr Gly Gly Met Ala Tyr
145          150          155          160

Glu Ala Met Asn His Ala Gly Asp Val Asn Ala Asn Leu Leu Val Ile
165          170          175

Leu Asn Asp Asn Asp Met Ser Ile Ser Pro Pro Val Gly Ala Met Asn
180          185          190

Asn Tyr Leu Thr Lys Val Leu Ser Ser Lys Phe Tyr Ser Ser Val Arg
195          200          205

Glu Glu Ser Lys Lys Ala Leu Ala Lys Met Pro Ser Val Trp Glu Leu
210          215          220

Ala Arg Lys Thr Glu Glu His Val Lys Gly Met Ile Val Pro Gly Thr
225          230          235          240

Leu Phe Glu Glu Leu Gly Phe Asn Tyr Phe Gly Pro Ile Asp Gly His
245          250          255

Asp Val Glu Met Leu Val Ser Thr Leu Glu Asn Leu Lys Asp Leu Thr
260          265          270

```

Gly Pro Val Phe Leu His Val Val Thr Lys Lys Gly Lys Gly Tyr Ala
 275 280 285
 Pro Ala Glu Lys Asp Pro Leu Ala Tyr His Gly Val Pro Ala Phe Asp
 290 295 300
 Pro Thr Lys Asp Phe Leu Pro Lys Ala Ala Pro Ser Pro His Pro Thr
 305 310 315 320
 Tyr Thr Glu Val Phe Gly Arg Trp Leu Cys Asp Met Ala Ala Gln Asp
 325 330 335
 Glu Arg Leu Leu Gly Ile Thr Pro Ala Met Arg Glu Gly Ser Gly Leu
 340 345 350
 Val Glu Phe Ser Gln Lys Phe Pro Asn Arg Tyr Phe Asp Val Ala Ile
 355 360 365
 Ala Glu Gln His Ala Val Thr Leu Ala Ala Gly Gln Ala Cys Gln Gly
 370 375 380
 Ala Lys Pro Val Val Ala Ile Tyr Ser Thr Phe Leu Gln Arg Gly Tyr
 385 390 395 400
 Asp Gln Leu Ile His Asp Val Ala Leu Gln Asn Leu Asp Met Leu Phe
 405 410 415
 Ala Leu Asp Arg Ala Gly Leu Val Gly Pro Asp Gly Pro Thr His Ala
 420 425 430
 Gly Ala Phe Asp Tyr Ser Tyr Met Arg Cys Ile Pro Asn Met Leu Ile
 435 440 445
 Met Ala Pro Ala Asp Glu Asn Glu Cys Arg Gln Met Leu Thr Thr Gly
 450 455 460
 Phe Gln His His Gly Pro Ala Ser Val Arg Tyr Pro Arg Gly Lys Gly
 465 470 475 480
 Pro Gly Ala Ala Ile Asp Pro Thr Leu Thr Ala Leu Glu Ile Gly Lys
 485 490 495
 Ala Glu Val Arg His His Gly Ser Arg Ile Ala Ile Leu Ala Trp Gly
 500 505 510
 Ser Met Val Thr Pro Ala Val Glu Ala Gly Lys Gln Leu Gly Ala Thr
 515 520 525
 Val Val Asn Met Arg Phe Val Lys Pro Phe Asp Gln Ala Leu Val Leu
 530 535 540
 Glu Leu Ala Arg Thr His Asp Val Phe Val Thr Val Glu Glu Asn Val
 545 550 555 560
 Ile Ala Gly Gly Ala Gly Ser Ala Ile Asn Thr Phe Leu Gln Ala Gln
 565 570 575
 Lys Val Leu Met Pro Val Cys Asn Ile Gly Leu Pro Asp Arg Phe Val
 580 585 590

Glu Gln Gly Ser Arg Glu Glu Leu Leu Ser Leu Val Gly Leu Asp Ser
 595 600 605

Lys Gly Ile Leu Ala Thr Ile Glu Gln Phe Cys Ala
 610 615 620

<210> 3
 <211> 1182
 <212> DNA
 <213> Methylomonas 16a

<220>
 <223> ORF2

<400> 3
 atgaaaggta tttgcatatt gggcgctacc ggttcgatcg gtgtcagcac gctggatgtc 60
 gttgccaggc atccggataa atatcaagtc gttgcgctga ccgccaacgg caatatcgac 120
 gcattgtatg aacaatgcct ggcccaccat ccggagtatg cgggtggtggt catggaaagc 180
 aaggtagcag agttcaaaca gcgcattgcc gcttcgcccg tagcggatat caaggtcttg 240
 tcgggtagcg aggccttgca acaggtggcc acgtggaaa acgtcgatac ggtgatggcg 300
 gctatcgtcg gcgcggcccg attggtgccg accttggccg cggccaaggc cggcaaaacc 360
 gtgctgttgg ccaacaagga agccttggtg atgtcgggac aaatcttcat gcaggccgtc 420
 agcgattccg gcgctgtgtt gctgccgata gacagcgagc acaacgccat ctttcagtgc 480
 atgccggcgg gttatacgcc aggccataca gccaaacagg cgcgccgcat tttattgacc 540
 gcttcgggtg gccatttcg acggacgccg atagaaacgt tgtccagcgt cacgccggat 600
 caggccgttg cccatcctaa atgggacatg gggcgcaaga ttccggtcga ttccgccacc 660
 atgatgaaca aagggtctcga actgatcgaa gcctgcttgt tgttcaacat ggagcccagc 720
 cagattgaag tcgtcattca tccgcagagc atcattcatt cgatggtgga ctatgtcgat 780
 ggttcggttt tggcgcatat gggtaatccc gacatgcgca cgcgcatagc gcacgcgatg 840
 gcctggcccg aacgctttga ctctggtgtg gcgcgctggt atattttcga agtagggcac 900
 atggatttcg aaaaaccoga cttgaaacgg tttccttgtc tgagattggc ttatgaagcc 960
 atcaagtctg gtggaattat gccaacggtg ttgaacgcag ccaatgaaat tgctgtcgaa 1020
 gcgtttttta atgaagaagt caaattcact gacatcgagg tcatcatcga gcgcagcatg 1080
 gccagttta aaccggacga tgccggcagc ctggaattgg ttttgcaggc cgatcaagat 1140
 gcgcgcgagg tggttagaga catcatcaag accttggtag ct 1182

<210> 4
 <211> 394
 <212> PRT
 <213> Methylomonas 16a

<220>
 <223> Amino acid sequences encoded by ORF2

<400> 4
 Met Lys Gly Ile Cys Ile Leu Gly Ala Thr Gly Ser Ile Gly Val Ser
 1 5 10 15
 Thr Leu Asp Val Val Ala Arg His Pro Asp Lys Tyr Gln Val Val Ala
 20 25 30
 Leu Thr Ala Asn Gly Asn Ile Asp Ala Leu Tyr Glu Gln Cys Leu Ala
 35 40 45
 His His Pro Glu Tyr Ala Val Val Val Met Glu Ser Lys Val Ala Glu
 50 55 60

Phe Lys Gln Arg Ile Ala Ala Ser Pro Val Ala Asp Ile Lys Val Leu
 65 70 75 80
 Ser Gly Ser Glu Ala Leu Gln Gln Val Ala Thr Leu Glu Asn Val Asp
 85 90 95
 Thr Val Met Ala Ala Ile Val Gly Ala Ala Gly Leu Leu Pro Thr Leu
 100 105 110
 Ala Ala Ala Lys Ala Gly Lys Thr Val Leu Leu Ala Asn Lys Glu Ala
 115 120 125
 Leu Val Met Ser Gly Gln Ile Phe Met Gln Ala Val Ser Asp Ser Gly
 130 135 140
 Ala Val Leu Leu Pro Ile Asp Ser Glu His Asn Ala Ile Phe Gln Cys
 145 150 155 160
 Met Pro Ala Gly Tyr Thr Pro Gly His Thr Ala Lys Gln Ala Arg Arg
 165 170 175
 Ile Leu Leu Thr Ala Ser Gly Gly Pro Phe Arg Arg Thr Pro Ile Glu
 180 185 190
 Thr Leu Ser Ser Val Thr Pro Asp Gln Ala Val Ala His Pro Lys Trp
 195 200 205
 Asp Met Gly Arg Lys Ile Ser Val Asp Ser Ala Thr Met Met Asn Lys
 210 215 220
 Gly Leu Glu Leu Ile Glu Ala Cys Leu Leu Phe Asn Met Glu Pro Asp
 225 230 235 240
 Gln Ile Glu Val Val Ile His Pro Gln Ser Ile Ile His Ser Met Val
 245 250 255
 Asp Tyr Val Asp Gly Ser Val Leu Ala Gln Met Gly Asn Pro Asp Met
 260 265 270
 Arg Thr Pro Ile Ala His Ala Met Ala Trp Pro Glu Arg Phe Asp Ser
 275 280 285
 Gly Val Ala Pro Leu Asp Ile Phe Glu Val Gly His Met Asp Phe Glu
 290 295 300
 Lys Pro Asp Leu Lys Arg Phe Pro Cys Leu Arg Leu Ala Tyr Glu Ala
 305 310 315 320
 Ile Lys Ser Gly Gly Ile Met Pro Thr Val Leu Asn Ala Ala Asn Glu
 325 330 335
 Ile Ala Val Glu Ala Phe Leu Asn Glu Glu Val Lys Phe Thr Asp Ile
 340 345 350
 Ala Val Ile Ile Glu Arg Ser Met Ala Gln Phe Lys Pro Asp Asp Ala
 355 360 365
 Gly Ser Leu Glu Leu Val Leu Gln Ala Asp Gln Asp Ala Arg Glu Val
 370 375 380

Ala Arg Asp Ile Ile Lys Thr Leu Val Ala
385 390

<210> 5
<211> 693
<212> DNA
<213> Methylomonas 16a

<220>
<223> ORF3

<400> 5
atgaacccaa ccatccaatg ctggggccgctc gtgcccgcag ccggcgcgcg caaacgcgatg 60
caagccgata gccccaaca atatttaccg cttgccggtg aaacgggtcat cgaacacaca 120
ctgactcgac tacttgagtc cgacgccttc caaaaagttg cgggtggcgat ttccgctgaa 180
gacccttatt ggcctgaact gtccatagcc aaacaccccg acatcatcac cgcgcctggc 240
ggcaaggaac gcgccgactc ggtgctgtct gcactgaagg ctttagaaga tatagccagc 300
gaaaatgatt ggggtgctgt acacgacgcc gcccgcccct gcttgacggg cagcgacatc 360
caccttcaaa tcgatacctt aaaaaatgac ccggtcggcg gcacccctggc cttgagttcg 420
cagcacacat tgaaacacgt ggatgggtgac acgatcaccg caaccataga cagaaagcac 480
gtctggcgcg ccttgacgcc gcaaattgtt aaatacggca tggtgcgcga cgcgttgcaa 540
cgaaccgaag gcaatccggc cgtaaccgac gaagccagtg cgctggaact tttgggccat 600
aaacccaaaa tcgtggaagg ccgcccggac aacatcaaaa tcaccgcgcc ggaagatttg 660
gccctggcac aattttatat ggagcaacaa gca 693

<210> 6
<211> 231
<212> PRT
<213> Methylomonas 16a

<220>
<223> Amino acid sequences encoded by ORF3

<400> 6
Met Asn Pro Thr Ile Gln Cys Trp Ala Val Val Pro Ala Ala Gly Val
1 5 10 15
Gly Lys Arg Met Gln Ala Asp Arg Pro Lys Gln Tyr Leu Pro Leu Ala
20 25 30
Gly Lys Thr Val Ile Glu His Thr Leu Thr Arg Leu Leu Glu Ser Asp
35 40 45
Ala Phe Gln Lys Val Ala Val Ala Ile Ser Val Glu Asp Pro Tyr Trp
50 55 60
Pro Glu Leu Ser Ile Ala Lys His Pro Asp Ile Ile Thr Ala Pro Gly
65 70 75 80
Gly Lys Glu Arg Ala Asp Ser Val Leu Ser Ala Leu Lys Ala Leu Glu
85 90 95
Asp Ile Ala Ser Glu Asn Asp Trp Val Leu Val His Asp Ala Ala Arg
100 105 110
Pro Cys Leu Thr Gly Ser Asp Ile His Leu Gln Ile Asp Thr Leu Lys
115 120 125

Asn Asp Pro Val Gly Gly Ile Leu Ala Leu Ser Ser His Asp Thr Leu
 130 135 140
 Lys His Val Asp Gly Asp Thr Ile Thr Ala Thr Ile Asp Arg Lys His
 145 150 155 160
 Val Trp Arg Ala Leu Thr Pro Gln Met Phe Lys Tyr Gly Met Leu Arg
 165 170 175
 Asp Ala Leu Gln Arg Thr Glu Gly Asn Pro Ala Val Thr Asp Glu Ala
 180 185 190
 Ser Ala Leu Glu Leu Leu Gly His Lys Pro Lys Ile Val Glu Gly Arg
 195 200 205
 Pro Asp Asn Ile Lys Ile Thr Arg Pro Glu Asp Leu Ala Leu Ala Gln
 210 215 220
 Phe Tyr Met Glu Gln Gln Ala
 225 230

<210> 7
 <211> 855
 <212> DNA
 <213> Methylobionas 16a

<220>
 <223> ORF4

<400> 7
 atggattatg cggctgggtg gggcgaaaga tggcctgctc cggcaaaatt gaacttaatg 60
 ttgaggatta cgggtcgcag gccagatggc tatcatctgt tgcaaacggt gtttcaaatg 120
 ctgatctat gcgattggtt gacgtttcat cgggttgatg atggccgcgt gacgctgcga 180
 aatccaatct cgggcgttcc agagcaggat gacttgactg ttcgggcggc taatttggtg 240
 aagtctcata cgggtctgtg gcgcggagtt tgtatcgata tcgagaaaaa tctgcctatg 300
 ggtggtggtt tgggtggtgg aagttccgat gctgctacaa ccttggtagt tctaaatcgg 360
 ctttggggct tgggcttgct gaagcgtgag ttgatggatt tgggcttgag gcttggtgcc 420
 gatgtgcctg tgtttgtggt tgggtgttcg gcctggggcg aaggtgtgag cgaggatttg 480
 caggcaataa cggtgccgga acaatgggtt gtcattcatta aaccggattg ccatgtgaat 540
 actggagaaa ttttttctgc agaaaatttg acaaggaata gtgcagtcgt tacaatgagc 600
 gactttcttg caggggataa tcggaatgat tgttcggaag tggtttgcaa gttatatcga 660
 ccggtgaaag atgcaatcga tgcgttggtt tgctatgcgg aagcgagatt gacggggacc 720
 ggtgcatgtg tgttcgctca gttttgtaac aaggaagatg ctgagagtgc gttagaagga 780
 ttgaaagatc ggtggctggt gttcttggtt aaaggcttga atcagctctg gctctacaag 840
 aaattagaac agggga 855

<210> 8
 <211> 285
 <212> PRT
 <213> Methylobionas 16a

<220>
 <223> Amino acid sequences encoded by ORF4

<400> 8
 Met Asp Tyr Ala Ala Gly Trp Gly Glu Arg Trp Pro Ala Pro Ala Lys
 1 5 10 15

Leu Asn Leu Met Leu Arg Ile Thr Gly Arg Arg Pro Asp Gly Tyr His
 20 25 30
 Leu Leu Gln Thr Val Phe Gln Met Leu Asp Leu Cys Asp Trp Leu Thr
 35 40 45
 Phe His Pro Val Asp Asp Gly Arg Val Thr Leu Arg Asn Pro Ile Ser
 50 55 60
 Gly Val Pro Glu Gln Asp Asp Leu Thr Val Arg Ala Ala Asn Leu Leu
 65 70 75 80
 Lys Ser His Thr Gly Cys Val Arg Gly Val Cys Ile Asp Ile Glu Lys
 85 90 95
 Asn Leu Pro Met Gly Gly Gly Leu Gly Gly Gly Ser Ser Asp Ala Ala
 100 105 110
 Thr Thr Leu Val Val Leu Asn Arg Leu Trp Gly Leu Gly Leu Ser Lys
 115 120 125
 Arg Glu Leu Met Asp Leu Gly Leu Arg Leu Gly Ala Asp Val Pro Val
 130 135 140
 Phe Val Phe Gly Cys Ser Ala Trp Gly Glu Gly Val Ser Glu Asp Leu
 145 150 155 160
 Gln Ala Ile Thr Leu Pro Glu Gln Trp Phe Val Ile Ile Lys Pro Asp
 165 170 175
 Cys His Val Asn Thr Gly Glu Ile Phe Ser Ala Glu Asn Leu Thr Arg
 180 185 190
 Asn Ser Ala Val Val Thr Met Ser Asp Phe Leu Ala Gly Asp Asn Arg
 195 200 205
 Asn Asp Cys Ser Glu Val Val Cys Lys Leu Tyr Arg Pro Val Lys Asp
 210 215 220
 Ala Ile Asp Ala Leu Leu Cys Tyr Ala Glu Ala Arg Leu Thr Gly Thr
 225 230 235 240
 Gly Ala Cys Val Phe Ala Gln Phe Cys Asn Lys Glu Asp Ala Glu Ser
 245 250 255
 Ala Leu Glu Gly Leu Lys Asp Arg Trp Leu Val Phe Leu Ala Lys Gly
 260 265 270
 Leu Asn Gln Ser Ala Leu Tyr Lys Lys Leu Glu Gln Gly
 275 280 285

<210> 9

<211> 471

<212> DNA

<213> Methylobionas 16a

<220>

<223> ORF5

```

<400> 9
atgatacgcg taggcatggg ttacgacgtg caccgtttca acgacggcga ccacatcatt 60
ttgggcggcg tcaaaatccc ttatgaaaaa ggcctggaag cccattccga cggcgacgtg 120
gtgctgcacg cattggccga cgocatcttg ggagccgccg ctttggggcga catcggcaaa 180
catttcccgg acaccgaccc caatttcaag ggcgccgaca gcagggtgct actgcgccac 240
gtgtacggca tcgtcaagga aaaaggctat aaactggtca acgcgcacgt gaccatcatc 300
gctcaggcgc cgaagatgct gccacacgtg cccggcatgc gcgccaacat tgccgccgat 360
ctggaaaccg atgtcgatct cattaatgta aaagccacga cgaccgagaa actgggcttt 420
gagggccgta aggaaggcat cgccgtgcag gctgtggtgt tgatagaacg c 471

```

<210> 10

<211> 157

<212> PRT

<213> Methylomonas 16a

<220>

<223> Amino acid sequences encoded by ORF5

<400> 10

```

Met Ile Arg Val Gly Met Gly Tyr Asp Val His Arg Phe Asn Asp Gly
 1             5             10             15

Asp His Ile Ile Leu Gly Gly Val Lys Ile Pro Tyr Glu Lys Gly Leu
          20             25             30

Glu Ala His Ser Asp Gly Asp Val Val Leu His Ala Leu Ala Asp Ala
          35             40             45

Ile Leu Gly Ala Ala Ala Leu Gly Asp Ile Gly Lys His Phe Pro Asp
          50             55             60

Thr Asp Pro Asn Phe Lys Gly Ala Asp Ser Arg Val Leu Leu Arg His
          65             70             75             80

Val Tyr Gly Ile Val Lys Glu Lys Gly Tyr Lys Leu Val Asn Ala Asp
          85             90             95

Val Thr Ile Ile Ala Gln Ala Pro Lys Met Leu Pro His Val Pro Gly
          100            105            110

Met Arg Ala Asn Ile Ala Ala Asp Leu Glu Thr Asp Val Asp Phe Ile
          115            120            125

Asn Val Lys Ala Thr Thr Thr Glu Lys Leu Gly Phe Glu Gly Arg Lys
          130            135            140

Glu Gly Ile Ala Val Gln Ala Val Val Leu Ile Glu Arg
          145            150            155

```

<210> 11

<211> 1632

<212> DNA

<213> Methylomonas 16a

<220>

<223> ORF6

<400> 11

```

atgacaaaat tcatctttat caccggcggc gtggtgtcat ccttgggaaa agggatagcc 60
gcctcctccc tggcggcgat tctggaagac cgcggcctca aagtcactat cacaaaaactc 120
gatccctaca tcaacgtcga ccccgccacc atgagcccgt ttcaacacgg cgagggtgttc 180
gtgaccgaag acggtgccga aaccgatttg gaccttggcc attacgaacg gtttttgaaa 240
accacgatga ccaagaaaaa caacttcacc accggtcagg ttacgagca ggtattacgc 300
aacgagcgca aaggtgatta tcttggcgcg accgtgcaag tcattccaca tatcaccgac 360
gaaatcaaac gccgggtgta tgaaagcgcc gaagggaaaag atgtggcatt gatcgaagtc 420
ggcggcacgg tgggcgacat cgaatcgtaa ccgtttcttg aaaccatacg ccagatgggc 480
gtggaactgg gtcgtgacgg cgccttggtt attcatttga cgctgggtgcc ttacatcaaa 540
tcggccggcg aactgaaaac caagcccacc cagcattcgg tcaaagaact gcgcaccatc 600
gggattcagc cggacatttt gatctgtcgt tcagaacaac cgatcccggc cagtgaacgc 660
cgcaagatcg cgctattttac caatgtcgcc gaaaaggcgg tgatttcgcg gatcgatgcc 720
gacaccattt accgcatttc gctattgctg cgcgaacaag gcctggacga cctggtggtc 780
gatcagttgc gcctggacgt accagcggcg gatttatcgg cctgggaaaa ggtcgtcgat 840
ggcctgactc atccgaccga cgaagtcagc attgcgatcg tcggtaaata tgtcgaccac 900
accgatgcct acaaatcgct gaatgaagcc ctgattcatg ccggcattca cacgcgccac 960
aaggtgcaaa tcagctacat cgactccgaa accatagaag ccgaaggcac cgccaaattg 1020
aaaaacgtcg atgcgatcct ggtgccgggt ggtttcggcg aacgcggcgt ggaaggcaag 1080
atttctaccg tgcgttttgc ccgcgagaac aaaatcccgt atttgggcgt ttgcttgggc 1140
atgcaatcgg cggtaatcga attcgccgcg aacgtgggtg gcctggaagg cgcgcacagc 1200
accgaatttc tgccgaaatc gccacaccct gtgatcggtg tgatcaccga atggatggac 1260
gaagccggcg aactggtcac acgcgacgaa gattccgatc tgggcggcac gatgcgtctg 1320
ggcgcgcaaa aatgccgcct gaaggctgat tccttggctt ttcagttgta tcaaaaagac 1380
gtcatcaccg agcgtcaccg ccaccgctac gaattcaaca atcaatattt aaaacaactg 1440
gaagcggcgg gcatgaaatt ttccggtaaa tcgctggacg gccgcctggt ggagatcatc 1500
gagctacccg aacaccccctg gttcctggcc tgccagttcc atcccgaatt cacctcgacg 1560
ccgcgtaacg gccacgccct attttcgggc ttcgtcgaag cggccgccaa acacaaaaca 1620
caaggcacag ca

```

<210> 12

<211> 544

<212> PRT

<213> Methylobionas 16a

<220>

<223> Amino acid sequences encoded by ORF6

<400> 12

```

Met Thr Lys Phe Ile Phe Ile Thr Gly Gly Val Val Ser Ser Leu Gly
  1             5             10             15

```

```

Lys Gly Ile Ala Ala Ser Ser Leu Ala Ala Ile Leu Glu Asp Arg Gly
          20             25             30

```

```

Leu Lys Val Thr Ile Thr Lys Leu Asp Pro Tyr Ile Asn Val Asp Pro
          35             40             45

```

```

Gly Thr Met Ser Pro Phe Gln His Gly Glu Val Phe Val Thr Glu Asp
          50             55             60

```

```

Gly Ala Glu Thr Asp Leu Asp Leu Gly His Tyr Glu Arg Phe Leu Lys
          65             70             75             80

```

```

Thr Thr Met Thr Lys Lys Asn Asn Phe Thr Thr Gly Gln Val Tyr Glu
          85             90             95

```

```

Gln Val Leu Arg Asn Glu Arg Lys Gly Asp Tyr Leu Gly Ala Thr Val
          100             105             110

```

Gln Val Ile Pro His Ile Thr Asp Glu Ile Lys Arg Arg Val Tyr Glu
 115 120 125
 Ser Ala Glu Gly Lys Asp Val Ala Leu Ile Glu Val Gly Gly Thr Val
 130 135 140
 Gly Asp Ile Glu Ser Leu Pro Phe Leu Glu Thr Ile Arg Gln Met Gly
 145 150 155 160
 Val Glu Leu Gly Arg Asp Arg Ala Leu Phe Ile His Leu Thr Leu Val
 165 170 175
 Pro Tyr Ile Lys Ser Ala Gly Glu Leu Lys Thr Lys Pro Thr Gln His
 180 185 190
 Ser Val Lys Glu Leu Arg Thr Ile Gly Ile Gln Pro Asp Ile Leu Ile
 195 200 205
 Cys Arg Ser Glu Gln Pro Ile Pro Ala Ser Glu Arg Arg Lys Ile Ala
 210 215 220
 Leu Phe Thr Asn Val Ala Glu Lys Ala Val Ile Ser Ala Ile Asp Ala
 225 230 235 240
 Asp Thr Ile Tyr Arg Ile Pro Leu Leu Leu Arg Glu Gln Gly Leu Asp
 245 250 255
 Asp Leu Val Val Asp Gln Leu Arg Leu Asp Val Pro Ala Ala Asp Leu
 260 265 270
 Ser Ala Trp Glu Lys Val Val Asp Gly Leu Thr His Pro Thr Asp Glu
 275 280 285
 Val Ser Ile Ala Ile Val Gly Lys Tyr Val Asp His Thr Asp Ala Tyr
 290 295 300
 Lys Ser Leu Asn Glu Ala Leu Ile His Ala Gly Ile His Thr Arg His
 305 310 315 320
 Lys Val Gln Ile Ser Tyr Ile Asp Ser Glu Thr Ile Glu Ala Glu Gly
 325 330 335
 Thr Ala Lys Leu Lys Asn Val Asp Ala Ile Leu Val Pro Gly Gly Phe
 340 345 350
 Gly Glu Arg Gly Val Glu Gly Lys Ile Ser Thr Val Arg Phe Ala Arg
 355 360 365
 Glu Asn Lys Ile Pro Tyr Leu Gly Ile Cys Leu Gly Met Gln Ser Ala
 370 375 380
 Val Ile Glu Phe Ala Arg Asn Val Val Gly Leu Glu Gly Ala His Ser
 385 390 395 400
 Thr Glu Phe Leu Pro Lys Ser Pro His Pro Val Ile Gly Leu Ile Thr
 405 410 415
 Glu Trp Met Asp Glu Ala Gly Glu Leu Val Thr Arg Asp Glu Asp Ser
 420 425 430

Asp Leu Gly Gly Thr Met Arg Leu Gly Ala Gln Lys Cys Arg Leu Lys
 435 440 445
 Ala Asp Ser Leu Ala Phe Gln Leu Tyr Gln Lys Asp Val Ile Thr Glu
 450 455 460
 Arg His Arg His Arg Tyr Glu Phe Asn Asn Gln Tyr Leu Lys Gln Leu
 465 470 475 480
 Glu Ala Ala Gly Met Lys Phe Ser Gly Lys Ser Leu Asp Gly Arg Leu
 485 490 495
 Val Glu Ile Ile Glu Leu Pro Glu His Pro Trp Phe Leu Ala Cys Gln
 500 505 510
 Phe His Pro Glu Phe Thr Ser Thr Pro Arg Asn Gly His Ala Leu Phe
 515 520 525
 Ser Gly Phe Val Glu Ala Ala Ala Lys His Lys Thr Gln Gly Thr Ala
 530 535 540

<210> 13
 <211> 891
 <212> DNA
 <213> *Methylobacterium* 16a

<220>
 <223> ORF7

<400> 13
 atgagtaaat tgaaagccta cctgaccgtc tgccaagaac gcgtcgagcg cgcgctggac 60
 gcccgctctgc ctgccgaaaa catactgcca caaaccttgc atcaggccat gcgctattcc 120
 gtattgaacg gcggcaaacg caaccggccc ttgttgactt atgcgaccgg tcaggctttg 180
 ggcttgccgg aaaacgtgct ggatgcgccg gcttgcgcgg tagaattcat ccatgtgtat 240
 tcgctgattc acgacgatct gccggccatg gacaacgatg atctgcgccg cggcaaaccg 300
 acctgtcaca aggcttacga cgaggccacc gccattttgg ccggcgacgc actgcaggcg 360
 ctggcctttg aagttctggc caacgacccc ggcatcaccg tcgatgcccc ggctcgctg 420
 aaaatgatca cggctttgac ccgcgccagc ggctctcaag gcatgggtggg cggccaagcc 480
 atcgatctcg gctccgtcgg ccgcaaattg acgtgcgcgg aactcgaaaa catgcatatc 540
 cacaagactg gcgccctgat ccgcgccagc gtcaatctgg cggcattatc caaaccgat 600
 ctggataact gcgtcgccaa gaaactggat cactatgcca aatgcatagg cttgtcgttc 660
 caggtcaaa acgacattct cgacatcgaa ccgcgacacc cgacactcgg caagactcag 720
 ggcaaggaca tcgataacga caaacggacc taccctgcgc tattgggcat ggctggcgcc 780
 aaacaaaaag ccaggaatt gcacgaacaa gcagtcgaaa gcttaacggg atttggcagc 840
 gaagccgacc tgctgcgcga actatcgctt tacatcatcg agcgcacgca c 891

<210> 14
 <211> 297
 <212> PRT
 <213> *Methylobacterium* 16a

<220>
 <223> Amino acid sequences encoded by ORF7

<400> 14
 Met Ser Lys Leu Lys Ala Tyr Leu Thr Val Cys Gln Glu Arg Val Glu
 1 5 10 15

Arg Ala Leu Asp Ala Arg Leu Pro Ala Glu Asn Ile Leu Pro Gln Thr
 20 25 30
 Leu His Gln Ala Met Arg Tyr Ser Val Leu Asn Gly Gly Lys Arg Thr
 35 40 45
 Arg Pro Leu Leu Thr Tyr Ala Thr Gly Gln Ala Leu Gly Leu Pro Glu
 50 55 60
 Asn Val Leu Asp Ala Pro Ala Cys Ala Val Glu Phe Ile His Val Tyr
 65 70 75 80
 Ser Leu Ile His Asp Asp Leu Pro Ala Met Asp Asn Asp Asp Leu Arg
 85 90 95
 Arg Gly Lys Pro Thr Cys His Lys Ala Tyr Asp Glu Ala Thr Ala Ile
 100 105 110
 Leu Ala Gly Asp Ala Leu Gln Ala Leu Ala Phe Glu Val Leu Ala Asn
 115 120 125
 Asp Pro Gly Ile Thr Val Asp Ala Pro Ala Arg Leu Lys Met Ile Thr
 130 135 140
 Ala Leu Thr Arg Ala Ser Gly Ser Gln Gly Met Val Gly Gly Gln Ala
 145 150 155 160
 Ile Asp Leu Gly Ser Val Gly Arg Lys Leu Thr Leu Pro Glu Leu Glu
 165 170 175
 Asn Met His Ile His Lys Thr Gly Ala Leu Ile Arg Ala Ser Val Asn
 180 185 190
 Leu Ala Ala Leu Ser Lys Pro Asp Leu Asp Thr Cys Val Ala Lys Lys
 195 200 205
 Leu Asp His Tyr Ala Lys Cys Ile Gly Leu Ser Phe Gln Val Lys Asp
 210 215 220
 Asp Ile Leu Asp Ile Glu Ala Asp Thr Ala Thr Leu Gly Lys Thr Gln
 225 230 235 240
 Gly Lys Asp Ile Asp Asn Asp Lys Pro Thr Tyr Pro Ala Leu Leu Gly
 245 250 255
 Met Ala Gly Ala Lys Gln Lys Ala Gln Glu Leu His Glu Gln Ala Val
 260 265 270
 Glu Ser Leu Thr Gly Phe Gly Ser Glu Ala Asp Leu Leu Arg Glu Leu
 275 280 285
 Ser Leu Tyr Ile Ile Glu Arg Thr His
 290 295

<210> 15

<211> 1533

<212> DNA

<213> Methylomonas 16a

<220>

<223> ORF8

<400> 15

```

atggccaaca ccaaacacat catcatcgtc ggcgcgggtc ccggcggact ttgcgccggc. 60
atgttgctga gccagcgcg gcttcaaggta tcgatttttcg acaaacatgc agaaatcggc 120
ggccgcaacc gcccgatcaa catgaacggc ttacaccttcg ataccggtcc gacattcttg 180
ttgatgaaag gcgtgctgga cgaaatgttc gaactgtgog agcgccgtag cgaggattat 240
ctggaattcc tgcogctaag cccgatgtac gcctgtgtgt acgacgaccg cgacatcttc 300
gtctattccg accgcgagaa catgcgcgcc gaattgcaac gggatttcga cgaaggcacg 360
gacggctacg aacagttcat ggaacaggaa cgcaaacgct tcaacgcgct gtatccctgc 420
atcaccgcg attattccag cctgaaatcc tttttgtcgc tggacttgat caaggccctg 480
ccgtggctgg cttttccgaa aagcgtgttc aataatctcg gccagtattt caaccaggaa 540
aaaatgcgcc tggccttttg ctttcagtcc aagtatctgg gcatgtcgcc gtgggaatgc 600
ccggcactgt ttacgatgct gccctatctg gagcacgaat acggcattta tcacgtcaaa 660
ggcggcctga accgcatcgc ggcggcgatg gcgcaagtga tcgcggaaaa cggcggcgaa 720
attcacttga acagcgaaat cgagtcgctg atcatcgaaa acggcgctgc caaggcgctc 780
aaattacaac atggcgcgga gctgcgcggc gacgaagtca tcatcaacgc ggattttgcc 840
cacgcgatga cgcactcggg caaacgcggc gtcttgaaaa aatacacccc ggaaaacctg 900
aagcagcgcg agtattcctg ttcgaccttc atgctgtatc tgggtttgga caagatttac 960
gatctgccgc accataccat cgtgtttgcc aaggattaca ccaccaatat ccgcaacatt 1020
ttcgacaaca aaaccctgac ggacgatttt tcgttttacg tgcaaaacgc cagcgccagc 1080
gacgacagcc tagcgccagc cggcaaactc gcgctgtacg tgctgggtgc gatgcccaac 1140
aacgacagcg gcctggactg gcaggcgcat tgccaaaacg tgcgcgaaca ggtgttgga 1200
acgctgggcg cgcgactggg attgagcgac atcagagccc atatcgaatg cgaaaaaatc 1260
atcacgccgc aaacctggga aacggacgaa cacgtttaca agggcgccac tttcagtttg 1320
tcgcacaagt tcagccaaat gctgtactgg cgcccgaca accgtttcga ggaactggcc 1380
aattgctatc tggtcggcgg cggcacgcat cccggtagcg gtttgccgac catctacgaa 1440
tcggcgcgga tttcggccaa gctgatttcc cagaaacatc gggtgaggtt caaggacata 1500
gcacacagcg cctggctgaa aaaagccaaa gcc 1533

```

<210> 16

<211> 511

<212> PRT

<213> Methylobionas 16a

<220>

<223> Amino acid sequences encoded by ORF8

<400> 16

```

Met Ala Asn Thr Lys His Ile Ile Ile Val Gly Ala Gly Pro Gly Gly
 1           5           10           15

Leu Cys Ala Gly Met Leu Leu Ser Gln Arg Gly Phe Lys Val Ser Ile
          20           25           30

Phe Asp Lys His Ala Glu Ile Gly Gly Arg Asn Arg Pro Ile Asn Met
          35           40           45

Asn Gly Phe Thr Phe Asp Thr Gly Pro Thr Phe Leu Leu Met Lys Gly
          50           55           60

Val Leu Asp Glu Met Phe Glu Leu Cys Glu Arg Arg Ser Glu Asp Tyr
          65           70           75           80

Leu Glu Phe Leu Pro Leu Ser Pro Met Tyr Arg Leu Leu Tyr Asp Asp
          85           90           95

```

Arg Asp Ile Phe Val Tyr Ser Asp Arg Glu Asn Met Arg Ala Glu Leu
 100 105 110
 Gln Arg Val Phe Asp Glu Gly Thr Asp Gly Tyr Glu Gln Phe Met Glu
 115 120 125
 Gln Glu Arg Lys Arg Phe Asn Ala Leu Tyr Pro Cys Ile Thr Arg Asp
 130 135 140
 Tyr Ser Ser Leu Lys Ser Phe Leu Ser Leu Asp Leu Ile Lys Ala Leu
 145 150 155 160
 Pro Trp Leu Ala Phe Pro Lys Ser Val Phe Asn Asn Leu Gly Gln Tyr
 165 170 175
 Phe Asn Gln Glu Lys Met Arg Leu Ala Phe Cys Phe Gln Ser Lys Tyr
 180 185 190
 Leu Gly Met Ser Pro Trp Glu Cys Pro Ala Leu Phe Thr Met Leu Pro
 195 200 205
 Tyr Leu Glu His Glu Tyr Gly Ile Tyr His Val Lys Gly Gly Leu Asn
 210 215 220
 Arg Ile Ala Ala Ala Met Ala Gln Val Ile Ala Glu Asn Gly Gly Glu
 225 230 235 240
 Ile His Leu Asn Ser Glu Ile Glu Ser Leu Ile Ile Glu Asn Gly Ala
 245 250 255
 Ala Lys Gly Val Lys Leu Gln His Gly Ala Glu Leu Arg Gly Asp Glu
 260 265 270
 Val Ile Ile Asn Ala Asp Phe Ala His Ala Met Thr His Leu Val Lys
 275 280 285
 Pro Gly Val Leu Lys Lys Tyr Thr Pro Glu Asn Leu Lys Gln Arg Glu
 290 295 300
 Tyr Ser Cys Ser Thr Phe Met Leu Tyr Leu Gly Leu Asp Lys Ile Tyr
 305 310 315 320
 Asp Leu Pro His His Thr Ile Val Phe Ala Lys Asp Tyr Thr Thr Asn
 325 330 335
 Ile Arg Asn Ile Phe Asp Asn Lys Thr Leu Thr Asp Asp Phe Ser Phe
 340 345 350
 Tyr Val Gln Asn Ala Ser Ala Ser Asp Asp Ser Leu Ala Pro Ala Gly
 355 360 365
 Lys Ser Ala Leu Tyr Val Leu Val Pro Met Pro Asn Asn Asp Ser Gly
 370 375 380
 Leu Asp Trp Gln Ala His Cys Gln Asn Val Arg Glu Gln Val Leu Asp
 385 390 395 400
 Thr Leu Gly Ala Arg Leu Gly Leu Ser Asp Ile Arg Ala His Ile Glu
 405 410 415

Cys Glu Lys Ile Ile Thr Pro Gln Thr Trp Glu Thr Asp Glu His Val
 420 425 430
 Tyr Lys Gly Ala Thr Phe Ser Leu Ser His Lys Phe Ser Gln Met Leu
 435 440 445
 Tyr Trp Arg Pro His Asn Arg Phe Glu Glu Leu Ala Asn Cys Tyr Leu
 450 455 460
 Val Gly Gly Gly Thr His Pro Gly Ser Gly Leu Pro Thr Ile Tyr Glu
 465 470 475 480
 Ser Ala Arg Ile Ser Ala Lys Leu Ile Ser Gln Lys His Arg Val Arg
 485 490 495
 Phe Lys Asp Ile Ala His Ser Ala Trp Leu Lys Lys Ala Lys Ala
 500 505 510

<210> 17

<211> 1491

<212> DNA

<213> Methylobionas 16a

<220>

<223> ORF9

<400> 17

```

atgaactcaa atgacaacca acgcgtgato gtgatcggcg ccggcctcgg cggcctgtcc 60
gccgtatatt cgctggccac ggccggcttt tccgtgcaac tcatcgaaaa aaacgacaag 120
gtcggcggca agctcaacat catgacaaaa gacggcttta ccttcgatct ggggccgtcc 180
atittgacga tgccgcacat ctttgaggcc ttgttcacag gggccggcaa aaacatggcc 240
gattacgtgc aaatccagaa agtcgaaccg cactggcgca atttcttcga ggacggtagc 300
gtgatcgact tgtgcgaaga cgccgaaacc cagcgccgcg agctggataa acttggcccc 360
ggcacttacg cgcaattcca gcgctttctg gactattcga aaaacctctg cacggaaacc 420
gaagccgggtt acttcgccaa gggcctggac ggcttttggg atttactcaa gttttacggc 480
ccgctccgca gcctgctgag ttctgacgtc ttccgcagca tggaccaggg cgtgcgccgc 540
tttatttccg atcccaagtt ggtcgaaatc ctgaattact tcatcaaata cgtcggctcc 600
tcgccttacg atgcgccgcg cttgatgaac ctgctgcctt acattcaata tcattacggc 660
ctgtggtagc tgaagggcgg catgtatggc atggcgagg ccattggaaaa actggccgtg 720
gaattgggag tcgagattcg ttttagatgcc gaggtgtcgg aaatccaaaa acaggacggc 780
agagcctgag ccgtaaaagt ggccgaacggc gacgtgctgc cggccgacat cgtgggtgctg 840
aacatggaag tgattccggc gatggaaaaa ctgctgcgca gcccgccag cgaactgaaa 900
aaaatgcagc gcttcgagcc tagctgttcc ggctgggtgc tgcacttggg cgtggacagg 960
ctgtatccgc aactggcgca ccacaatttc ttttattccg atcatccgcg cgaacatttc 1020
gatgcgggat tcaaaagcca tcgcctgtcg gacgatccga ccatttatct ggtcgcgccg 1080
tgcaagaccg accccgcccc ggccgcggcc ggctgcgaga tcatcaaaat cctgccccat 1140
atcccgcaac tcgacccccg caaactgctg accgcccagg attattcagc cttgcgcgag 1200
cgggtgctgg tcaaaactcg acgcatgggc ctgacggatt tacgccaaca catcgtgacc 1260
gaagaatact ggacgcccgt ggatattcag gccaaatatt attcaaacca gggctcgatt 1320
tacggcgtgg tcgcccagcc cttcaaaaac ctgggtttca aggcacctca acgcagcagc 1380
gaattatcca atctgtatatt cgtcggcggc agcgtcaatc ccggcggcgg catgccgatg 1440
gtgacgctgt ccgggcaatt ggtgagggac aagattgtgg cggatttgca a 1491

```

<210> 18

<211> 497

<212> PRT

<213> Methylobionas 16a

<220>

<223> Amino acid sequences encoded by ORF9

<400> 18

```

Met Asn Ser Asn Asp Asn Gln Arg Val Ile Val Ile Gly Ala Gly Leu
 1           5           10           15

Gly Gly Leu Ser Ala Ala Ile Ser Leu Ala Thr Ala Gly Phe Ser Val
          20           25           30

Gln Leu Ile Glu Lys Asn Asp Lys Val Gly Gly Lys Leu Asn Ile Met
          35           40           45

Thr Lys Asp Gly Phe Thr Phe Asp Leu Gly Pro Ser Ile Leu Thr Met
          50           55           60

Pro His Ile Phe Glu Ala Leu Phe Thr Gly Ala Gly Lys Asn Met Ala
          65           70           75           80

Asp Tyr Val Gln Ile Gln Lys Val Glu Pro His Trp Arg Asn Phe Phe
          85           90           95

Glu Asp Gly Ser Val Ile Asp Leu Cys Glu Asp Ala Glu Thr Gln Arg
          100          105          110

Arg Glu Leu Asp Lys Leu Gly Pro Gly Thr Tyr Ala Gln Phe Gln Arg
          115          120          125

Phe Leu Asp Tyr Ser Lys Asn Leu Cys Thr Glu Thr Glu Ala Gly Tyr
          130          135          140

Phe Ala Lys Gly Leu Asp Gly Phe Trp Asp Leu Leu Lys Phe Tyr Gly
          145          150          155          160

Pro Leu Arg Ser Leu Leu Ser Phe Asp Val Phe Arg Ser Met Asp Gln
          165          170          175

Gly Val Arg Arg Phe Ile Ser Asp Pro Lys Leu Val Glu Ile Leu Asn
          180          185          190

Tyr Phe Ile Lys Tyr Val Gly Ser Ser Pro Tyr Asp Ala Pro Ala Leu
          195          200          205

Met Asn Leu Leu Pro Tyr Ile Gln Tyr His Tyr Gly Leu Trp Tyr Val
          210          215          220

Lys Gly Gly Met Tyr Gly Met Ala Gln Ala Met Glu Lys Leu Ala Val
          225          230          235          240

Glu Leu Gly Val Glu Ile Arg Leu Asp Ala Glu Val Ser Glu Ile Gln
          245          250          255

Lys Gln Asp Gly Arg Ala Cys Ala Val Lys Leu Ala Asn Gly Asp Val
          260          265          270

Leu Pro Ala Asp Ile Val Val Ser Asn Met Glu Val Ile Pro Ala Met
          275          280          285

Glu Lys Leu Leu Arg Ser Pro Ala Ser Glu Leu Lys Lys Met Gln Arg
          290          295          300

```

Phe Glu Pro Ser Cys Ser Gly Leu Val Leu His Leu Gly Val Asp Arg
 305 310 315 320
 Leu Tyr Pro Gln Leu Ala His His Asn Phe Phe Tyr Ser Asp His Pro
 325 330 335
 Arg Glu His Phe Asp Ala Val Phe Lys Ser His Arg Leu Ser Asp Asp
 340 345 350
 Pro Thr Ile Tyr Leu Val Ala Pro Cys Lys Thr Asp Pro Ala Gln Ala
 355 360 365
 Pro Ala Gly Cys Glu Ile Ile Lys Ile Leu Pro His Ile Pro His Leu
 370 375 380
 Asp Pro Asp Lys Leu Leu Thr Ala Glu Asp Tyr Ser Ala Leu Arg Glu
 385 390 395 400
 Arg Val Leu Val Lys Leu Glu Arg Met Gly Leu Thr Asp Leu Arg Gln
 405 410 415
 His Ile Val Thr Glu Glu Tyr Trp Thr Pro Leu Asp Ile Gln Ala Lys
 420 425 430
 Tyr Tyr Ser Asn Gln Gly Ser Ile Tyr Gly Val Val Ala Asp Arg Phe
 435 440 445
 Lys Asn Leu Gly Phe Lys Ala Pro Gln Arg Ser Ser Glu Leu Ser Asn
 450 455 460
 Leu Tyr Phe Val Gly Gly Ser Val Asn Pro Gly Gly Gly Met Pro Met
 465 470 475 480
 Val Thr Leu Ser Gly Gln Leu Val Arg Asp Lys Ile Val Ala Asp Leu
 485 490 495
 Gln

<210> 19

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 19

aaggatccgc gtattcgtag tc

22

<210> 20

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 20
 ctggatccga tctagaaata ggctcgagtt gtcgttcagg 40

<210> 21
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:primer

<400> 21
 aaggatccta ctcgagctga catcagtgc 30

<210> 22
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:primer

<400> 22
 gctctagatg caaccagaat cg 22

<210> 23
 <211> 954
 <212> DNA
 <213> Methylomonas 16a

<400> 23
 atgcaaatacg tactcgcaaa cccccgtgga ttctgtgccg gcgtggaccg ggccattgaa 60
 attgtcgatc aagccatcga agcctttggt gcgccgattt atgtgcggca cgaggtggtg 120
 cataaccgca cgtgtgtcga tggactgaaa caaaaagggtg cgtgtttcat cgaggaacta 180
 agcgatgtgc cgtgtggttc ctacttgatt ttcagcgcgc acggcgtatc caaggaggtg 240
 caacaggaag ccgaggagcg ccagttgacg gtattcgatg cgacttgacc gctggtgacc 300
 aaagtgcaca tgcaggttgc caagcatgcc aaacagggcc gagaagtgat tttgatcggc 360
 cagccggtc atccggaagt ggaaggcacg atgggccagt atgaaaaatg caccgaaggc 420
 ggccgcattt atctggtcga aactccggaa gacgtacgca atttgaaagt caacaatccc 480
 aatgatctgg cctatgtgac gcagacgacc ttgtcgatga ccgacaccaa ggtcatggtg 540
 gatgcgttac gcgaacaatt tccgtccatt aaggagcaaa aaaaggacga tttttgttac 600
 gcgacgcaaa accgtcagga tgcggtgcat gatctggcca agatttccga cctgattctg 660
 gttgtcggct ctccaatag ttogaattcc aaccgtttgc gtgaaatcgc cgtgcaactc 720
 ggtaaaccgg cttatttgat cgatacttac caggatttga agcaagattg gctggaggga 780
 attgaagtag tcgggggttac cgcgggcgct tcggcgccgg aagtgttggt gcaggaagtg 840
 atcgatcaac tgaaggcatg gggcggcgaa accacttcgg tcagagaaaa cagcggcatc 900
 gaggaaaagg tagtcttttc gattcccaag gagttgaaaa aacatatgca agcg 954

<210> 24
 <211> 318
 <212> PRT
 <213> Methylomonas 16a

<400> 24

```

Met Gln Ile Val Leu Ala Asn Pro Arg Gly Phe Cys Ala Gly Val Asp
 1           5           10           15

Arg Ala Ile Glu Ile Val Asp Gln Ala Ile Glu Ala Phe Gly Ala Pro
          20           25           30

Ile Tyr Val Arg His Glu Val Val His Asn Arg Thr Val Val Asp Gly
 35           40           45

Leu Lys Gln Lys Gly Ala Val Phe Ile Glu Glu Leu Ser Asp Val Pro
 50           55           60

Val Gly Ser Tyr Leu Ile Phe Ser Ala His Gly Val Ser Lys Glu Val
 65           70           75           80

Gln Gln Glu Ala Glu Glu Arg Gln Leu Thr Val Phe Asp Ala Thr Cys
          85           90           95

Pro Leu Val Thr Lys Val His Met Gln Val Ala Lys His Ala Lys Gln
          100          105          110

Gly Arg Glu Val Ile Leu Ile Gly His Ala Gly His Pro Glu Val Glu
          115          120          125

Gly Thr Met Gly Gln Tyr Glu Lys Cys Thr Glu Gly Gly Gly Ile Tyr
          130          135          140

Leu Val Glu Thr Pro Glu Asp Val Arg Asn Leu Lys Val Asn Asn Pro
          145          150          155          160

Asn Asp Leu Ala Tyr Val Thr Gln Thr Thr Leu Ser Met Thr Asp Thr
          165          170          175

Lys Val Met Val Asp Ala Leu Arg Glu Gln Phe Pro Ser Ile Lys Glu
          180          185          190

Gln Lys Lys Asp Asp Ile Cys Tyr Ala Thr Gln Asn Arg Gln Asp Ala
          195          200          205

Val His Asp Leu Ala Lys Ile Ser Asp Leu Ile Leu Val Val Gly Ser
          210          215          220

Pro Asn Ser Ser Asn Ser Asn Arg Leu Arg Glu Ile Ala Val Gln Leu
          225          230          235          240

Gly Lys Pro Ala Tyr Leu Ile Asp Thr Tyr Gln Asp Leu Lys Gln Asp
          245          250          255

Trp Leu Glu Gly Ile Glu Val Val Gly Val Thr Ala Gly Ala Ser Ala
          260          265          270

Pro Glu Val Leu Val Gln Glu Val Ile Asp Gln Leu Lys Ala Trp Gly
          275          280          285

Gly Glu Thr Thr Ser Val Arg Glu Asn Ser Gly Ile Glu Glu Lys Val
          290          295          300

Val Phe Ser Ile Pro Lys Glu Leu Lys Lys His Met Gln Ala
          305          310          315

```

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 March 2002 (14.03.2002)

PCT

(10) International Publication Number
WO 02/020733 A3

(51) International Patent Classification⁷: **C12N 15/52**,
9/88, C12P 23/00

CH-8003 Zuerich (CH). **TOMB, Jean-Francois** [US/US];
627 Haverhill Road, Wilmington, DE 19803 (US).

(21) International Application Number: PCT/US01/26852

(74) Agent: **FELTHAM, S., Neil**; E.I. Dupont de Nemours
and Company, Legal Patent Records Center, 4417 Lances-
ter Pike, Wilmington, DE 19805 (US).

(22) International Filing Date: 29 August 2001 (29.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/229,907 1 September 2000 (01.09.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(71) Applicant (*for all designated States except US*): **E.I. DUPONT DE NEMOURS AND COMPANY** [US/US];
Legal Patent Records Center, 1007 Market Street, Wilm-
ington, DE 19898 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CHENG, Qiong**
[CN/US]; 4 Collins Drive, Wilmington, DE 19803 (US).
KOFFAS, Mattheos [GR/US]; 1013 Cloister Road,
Apartment D, Wilmington, DE 19809 (US). **NORTON,**
Kelley, C. [US/US]; 8 Sullivan Chase Drive, Avondale,
PA 19311 (US). **ODOM, James, M.** [US/US]; 19 Fern
Hill Road, Kennett Square, PA 19348 (US). **PICATAG-**
GIO, Stephen, K. [US/US]; 17 Meadow Wood Lane,
Landenberg, PA 19350 (US). **ROUVIERE, Pierre, E.**
[FR/US]; 737 Taunton Road, Wilmington, DE 19803 (US).
SCHENZLE, Andreas [DE/CH]; Badenerstrasse 363,

Published:

— with international search report

(88) Date of publication of the international search report:
14 August 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: GENES INVOLVED IN ISOPRENOID COMPOUND PRODUCTION

(57) Abstract: Genes have been isolated from *Methylobionas 16a sp.* encoding the isoprenoid biosynthetic pathway. The genes and gene products are the first isolated from a *Methylobionas* strain that is capable of utilizing single carbon (C1) substrates as energy sources. The genes and gene products of the present invention may be used in a variety of ways for the production of isoprenoid compounds in a variety of organisms.

WO 02/020733 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/26852

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/52 C12N9/88 C12P23/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, MEDLINE, EMBASE, EPO-Internal, WPI Data, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RODRIGUEZ-CONCEPCION M ET AL: "Genetic evidence of branching in the isoprenoid pathway for the production of isopentenyl diphosphate and dimethylallyl diphosphate in Escherichia coli" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 473, no. 3, 19 May 2000 (2000-05-19), pages 328-332, XP002181415 ISSN: 0014-5793 the whole document --- -/--	1-35



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 February 2003

Date of mailing of the international search report

'07.03.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fotaki, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/26852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ROHMER M: "ISOPRENOID BIOSYNTHESIS VIA THE MEVALONATE-INDEPENDENT ROUTE, A NOVEL TARGET FOR ANTIBACTERIAL DRUGS?" PROGRESS IN DRUG RESEARCH, BASEL: BIRKHAUSER, CH, vol. 50, 1998, pages 135-154, XP000906878 ISBN: 3-7643-5821-1 the whole document	1-35
X	LOIS ET AL: "Cloning and characterization of a gene from Escherichia coli encoding a transketolase-like enzyme that catalyzes the synthesis of D-1-deoxyxylulose 5-phosphate, a common precursor for isoprenoid, thiamin, and pyridoxol biosynthesis" FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 95, March 1998 (1998-03), pages 2105-2110, XP002116673 ISSN: 0892-6638 cited in the application	1,3, 15-22
Y	page 2105 -page 2110	2,4,5, 23-35
X	WO 99 58649 A (UNIV MARYLAND ;DELLAPENNA DEAN (US); MOEHS CHARLES P (US); CUNNING) 18 November 1999 (1999-11-18)	1,3, 15-22
Y	page 1 -page 20	2,4,5, 23-35
X	WO 00 44912 A (BRAMLEY PETER MICHAEL ;HARKER MARK (GB); ROYAL HOLLOWAY AND BEDFOR) 3 August 2000 (2000-08-03)	1,3, 15-22
Y	page 1 -page 29	2,4,5, 23-35
X	WO 99 11757 A (MCCASKILL DAVID G ;LANGE BERND M (US); UNIV WASHINGTON (US); WILDU) 11 March 1999 (1999-03-11)	1,3, 15-22
Y	page 1 -page 15	2,4,5, 23-35
P,X	EP 1 072 683 A (KYOWA HAKKO KOGYO KK) 31 January 2001 (2001-01-31) the whole document	1,3, 15-22,35
X	WO 97 35966 A (MAXYGEN INC ;MINSHULL JEREMY (US); STEMMER WILLEM P C (US)) 2 October 1997 (1997-10-02) page 1-35 page 56	35

-/-

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TAKAHASHI S ET AL: "A 1-deoxy-D-xylulose 5-phosphate reductoisomerase catalyzing the formation of 2-C-methyl-D-erythritol 4-phosphate in an alternative nonmevalonate pathway for terpenoid biosynthesis" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, August 1998 (1998-08), pages 9879-9884, XP002136183 ISSN: 0027-8424 cited in the application	1,3,6, 15-22
Y	the whole document	2,4, 23-35
X	WO 00 34448 A (DU PONT ;LEE JIAN MING (US); TAO YONG (US); CAHOON REBECCA E (US)) 15 June 2000 (2000-06-15)	1,3, 15-22
Y	page 1 -page 29	2,4,6, 23-35
X	WO 00 46346 A (LANGE BERND M ;UNIV WASHINGTON (US); CROTEAU RODNEY B (US)) 10 August 2000 (2000-08-10)	1,3, 15-22,35
Y	page 1 -page 37	2,4,6, 23-34
X	KUZUYAMA TOMOHISA ET AL: "Characterization of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, an enzyme involved in isopentenyl diphosphate biosynthesis, and identification of its catalytic amino acid residues." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 26, 30 June 2000 (2000-06-30), pages 19928-19932, XP001119179 ISSN: 0021-9258 the whole document	35
P,X	WO 00 63389 A (BORONAT ALBERT ;BHAT B GANESH (US); CALGENE LLC (US); KISHORE GANE) 26 October 2000 (2000-10-26)	1,3, 15-22,35
P,X	WO 00 65036 A (LICHTENTHALER HARTMUT ;BASF AG (DE); HERBERS KARIN (DE); REINDL AN) 2 November 2000 (2000-11-02)	1,3, 15-22,35
	page 1 -page 28	

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/26852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HEIDELBERG JOHN F ET AL: "DNA sequence of both chromosomes of the cholera pathogen <i>Vibrio cholerae</i> ." NATURE (LONDON), vol. 406, no. 6795, 2000, pages 477-483, XP001120242 ISSN: 0028-0836	1,3,7, 15-22
Y	page 477 -page 484	2,4, 23-35
X	ROHDICH ET AL: "Cytidine 5'-triphosphate-dependent biosynthesis of isoprenoids: YgbP protein of <i>Escherichia coli</i> catalyzes the formation of 4-diphosphocytidyl-2-C-methylerythritol" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 21, 12 October 1999 (1999-10-12), pages 11758-11763, XP002154080 ISSN: 0027-8424 cited in the application	1,3,7, 15-22
Y	the whole document	2,4, 23-35
P,X	EP 1 043 403 A (GPC AG GENOME PHARMACEUTICALS) 11 October 2000 (2000-10-11) page 1 -page 17	1,3, 15-22,35
P,X	WO 00 61792 A (LABISCHINSKI HARALD ;WIELAND BERND (DE); BAYER AG (DE); BROETZ HEI) 19 October 2000 (2000-10-19) page 1 -page 34	1,3, 15-22
P,X	WO 00 61793 A (GPC BIOTECH AG ;LOFERER HANNES (DE); JACOBI ALEXANDER (DE)) 19 October 2000 (2000-10-19) page 1 -page 34	1,3, 15-22
P,X	WO 01 11055 A (EISENREICH WOLFGANG ;WUNGSINTAWEEKUL JURATHIP (DE); HERZ STEFAN () 15 February 2001 (2001-02-15) page 1 -page 137	1,3, 15-22
E	WO 01 83769 A (BOWMAN MARIANNE E ;NOEL JOSEPH P (US); RICHARD STEPHANE (US); SALK) 8 November 2001 (2001-11-08) page 1 -page 159	1,3, 15-22
E	WO 01 94561 A (EISENREICH WOLFGANG ;WUNGSINTAWEEKUL JURATHIP (DE); ROHDICH FELIX) 13 December 2001 (2001-12-13) page 1 -page 80	1,3, 15-22
	--- -/-	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/26852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LÜTTGEN ET AL: "Biosynthesis of terpenoids: YchB protein of Escherichia coli phosphorylates the 2-hydroxy group of 4-diphosphocytidyl-2C-methyl-D-erythritol"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 3, 1 February 2000 (2000-02-01), pages 1062-1067, XP002154082 ISSN: 0027-8424 cited in the application the whole document</p>	1,3,8, 15-22
X	<p>LANGE M ET AL: "ISOPENTENYL DIPHOSPHATE BISYNTHESIS VIA A MEVALONATE-INDEPENDENT PATHWAY: ISOPENTENYL MONOPHOSPHATE KINASE CATALYZES THE TERMINAL ENZYMIC STEP"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 24, 23 November 1999 (1999-11-23), pages 13714-13719, XP002943025 ISSN: 0027-8424 the whole document</p>	1,3, 15-22
X	<p>HERZ ET AL: "Biosynthesis of terpenoids: YgbB protein converts 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate to 2C-methyl-D-erythritol 2,4-cyclodiphosphate"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 6, 14 March 2000 (2000-03-14), pages 2486-2490, XP002154081 ISSN: 0027-8424 cited in the application the whole document</p>	1,3,9, 15-22
X	<p>TAKAGI M ET AL: "Studies on the nonmevalonate pathway: formation of 2-C-methyl-d-erythritol 2,4-cyclodiphosphate from 2-phospho-4-(cytidine 5'-diphospho)-2-C-methyl-d-erythritol"</p> <p>TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 41, no. 18, April 2000 (2000-04), pages 3395-3398, XP004198046 ISSN: 0040-4039 the whole document</p>	1,3, 15-22

-/-

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WENG M ET AL: "NUCLEOTIDE SEQUENCE OF ESCHERICHIA-COLI PYR-G ENCODING CTP SYNTHETASE"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 261, no. 12, 1986, pages 5568-5574, XP001119392</p> <p>ISSN: 0021-9258</p> <p>the whole document</p> <p>----</p>	1,3,10, 15-22
X	<p>DATABASE 'Online!</p> <p>retrieved from SWISS PROT</p> <p>Database accession no. P44341</p> <p>XP002222354</p> <p>abstract</p> <p>----</p>	1,3,10
X	<p>DATABASE 'Online!</p> <p>retrieved from EMBL</p> <p>Database accession no. AE004315</p> <p>XP002222355</p> <p>abstract</p> <p>----</p>	1,3,10
X	<p>OZIER-KALOGEROPOULOS ODILE ET AL: "Use of synthetic lethal mutants to clone and characterize a novel CTP synthetase gene in Saccharomyces cerevisiae."</p> <p>MOLECULAR & GENERAL GENETICS, vol. 242, no. 4, 1994, pages 431-439, XP001119391</p> <p>ISSN: 0026-8925</p> <p>the whole document</p> <p>----</p>	35
X	<p>STOVER C K ET AL: "COMPLETE GENOME SEQUENCE OF PSEUDOMONAS AERUGINOSA PA01, AN OPPORTUNISTIC PATHOGEN"</p> <p>NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 406, no. 6799, 31 August 2000 (2000-08-31), pages 959-964, XP000996980</p> <p>ISSN: 0028-0836</p> <p>the whole document</p> <p>----</p>	1,3,11, 15-22
X	<p>OHTO CHIKARA ET AL: "A thermophilic cyanobacterium Synechococcus elongatus has three different Class I prenyltransferase genes."</p> <p>PLANT MOLECULAR BIOLOGY, vol. 40, no. 2, May 1999 (1999-05), pages 307-321, XP001120099</p> <p>ISSN: 0167-4412</p> <p>cited in the application</p> <p>the whole document</p> <p>----</p> <p>-----</p>	1,3, 15-22

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OHNUMA S-I ET AL: "CONVERSION FROM FARNESYL DIPHOSPHATE SYNTHASE TO GERANYLGERANYL DIPHOSPHATE SYNTHASE BY RANDOM CHEMICAL MUTAGENESIS" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 17, 26 April 1996 (1996-04-26), pages 10087-10095, XP002059505 ISSN: 0021-9258 the whole document	1,3, 15-22,35
X	EP 0 816 490 A (TOYOTA MOTOR CO LTD) 7 January 1998 (1998-01-07) page 1 -page 11	1,3, 15-22,35
X	EP 0 955 363 A (HOFFMANN LA ROCHE) 10 November 1999 (1999-11-10) page 1 -page 18	1,3, 15-22
X	EP 0 974 661 A (TOYOTA MOTOR CO LTD) 26 January 2000 (2000-01-26) page 1 -page 11	1,3, 15-22,35
X	US 6 107 058 A (WILDING EDWINA IMOGEN ET AL) 22 August 2000 (2000-08-22) column 1-28	1,3, 15-22
P,X	EP 1 063 297 A (KOREA KUMHO PETROCHEM CO LTD) 27 December 2000 (2000-12-27) page 1 -page 17	1,3, 15-22
X	FONTES MARTA ET AL: "Growth phase dependence of the activation of a bacterial gene for carotenoid synthesis by blue light." EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 12, no. 4, 1993, pages 1265-1275, XP001120455 ISSN: 0261-4189 the whole document	1,3,12, 15-22
X	BOTELLA J A ET AL: "A CLUSTER OF STRUCTURAL AND REGULATORY GENES FOR LIGHT-INDUCED CAROTENOGENESIS IN MYXOCOCCUS XANTHUS" EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 233, no. 1, 1 October 1995 (1995-10-01), pages 238-248, XP000578408 ISSN: 0014-2956 the whole document	1,3,12, 15-22
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/26852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>XIONG JIN ET AL: "Tracking molecular evolution of photosynthesis by characterization of a major photosynthesis gene cluster from <i>Heliobacillus mobilis</i>." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 25, December 1998 (1998-12), pages 14851-14856, XP001120456 Dec., 1998 ISSN: 0027-8424 the whole document</p>	1,3,12, 15-22
X	<p>US 5 530 189 A (AUSICH RODNEY L ET AL) 25 June 1996 (1996-06-25) column 2-26 column 63-70</p>	1,3, 15-22
X	<p>WIELAND BERND ET AL: "Genetic and Biochemical Analyses of the Biosynthesis of the Yellow Carotenoid 4,4'-Diaponeurosporene of <i>Staphylococcus aureus</i>." JOURNAL OF BACTERIOLOGY, vol. 176, no. 24, 1994, pages 7719-7726, XP001120344 ISSN: 0021-9193 the whole document</p>	1,3, 15-22
P,X	<p>KURODA M ET AL: "Whole genome sequencing of meticillin-resistant <i>Staphylococcus aureus</i>" LANCET THE, LANCET LIMITED. LONDON, GB, vol. 357, no. 9264, 21 April 2001 (2001-04-21), pages 1225-1240, XP004246103 ISSN: 0140-6736 the whole document</p>	1,3,13, 15-22
X	<p>CUNNINGHAM F X JR ET AL: "Evidence of a role for LytB in the nonmevalonate pathway of isoprenoid biosynthesis" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 182, no. 20, October 2000 (2000-10), pages 5841-5848, XP002192766 ISSN: 0021-9193 the whole document</p>	1,3, 15-22
	<p>---</p> <p style="text-align: center;">-/--</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/26852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ALTINCICEK A B ET AL: "LytB, a novel gene of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis in Escherichia coli" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 499, no. 1-2, 15 June 2001 (2001-06-15), pages 37-40, XP004246982 ISSN: 0014-5793 the whole document -----	1,3, 15-22
E	WO 01 85950 A (JOMAA PHARMAKA GMBH ;JOMAA HASSAN (DE)) 15 November 2001 (2001-11-15) page 1-10 -----	1,3, 15-22